<SEC-DOCUMENT>0001193125-19-080946.txt : 20190320
<SEC-HEADER>0001193125-19-080946.hdr.sgml : 20190320
<ACCEPTANCE-DATETIME>20190320171302
ACCESSION NUMBER:		0001193125-19-080946
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20190320
DATE AS OF CHANGE:		20190320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229499
		FILM NUMBER:		19695254

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d723059d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-229499 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus Dated February&nbsp;12, 2019) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>7,200,000 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g723059g92q50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 7,200,000
shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TORC.&#148; The last reported sale price
of our common stock on the Nasdaq Global Select Market on March&nbsp;19, 2019 was $6.98 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase
up to 1,080,000 additional shares of common stock from us at the public offering price, less underwriting discounts and commissions, within 30 days of the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as the term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with
certain reduced public company reporting requirements. See &#147;Prospectus Supplement Summary&#151;Corporate Information.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common
stock involves a high degree of risk. See &#147;<A HREF="#suptoc723059_5">Risk Factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement and the risk factors described in the documents
incorporated by reference in this prospectus supplement and the accompanying prospectus to read about factors you should consider before purchasing our common stock. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,040,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$3,002,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to resTORbio, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,037,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission (the &#147;SEC&#148;) nor any other regulatory body has approved or disapproved of
these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock will be made on or about March&nbsp;22, 2019. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Guggenheim&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Wedbush PacGrow </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The
date of this prospectus supplement is March&nbsp;19, 2019. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<A NAME="toc"></A>ABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_17">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S.
HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_8a">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_9">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_12">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc723059_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_3">Cautionary Statement Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_4">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_6">Securities We May Offer or That a Selling Stockholder May
Offer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_7">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_8">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_9">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_10">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_11">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_12">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_15">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_16">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is part of the registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&#147;shelf&#148; registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering. The second part, the accompanying
prospectus dated February&nbsp;12, 2019, included in our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-229499)</FONT> including the documents incorporated by reference,
gives more general information, some of which may not apply to this offering. Generally, when we refer to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement and any related free writing prospectus we
authorize for use in connection with this offering may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by reference
that was filed with the SEC before the date of this prospectus supplement, you should rely on this prospectus supplement. This prospectus supplement, the accompanying prospectus, the documents incorporated by reference into each and any free writing
prospectus we authorize for use in connection with this offering include important information about us, the common stock and other information should you consider before investing in the common stock. See &#147;Incorporation of Certain Information
by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an
exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be
deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties and covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as
accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We take no responsibility for, and can provide no assurances as to the
reliability of, any information that is in addition to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We are not offering to sell these securities in any jurisdiction
where the offer or sale is not permitted. You should not assume that the information contained or incorporated by reference in this prospectus supplement or the accompanying prospectus is accurate as of any date other than as of the date of this
prospectus supplement or the accompanying prospectus, as the case may be, or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus supplement and the accompanying
prospectus or any sale of our securities. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus supplement or the accompanying prospectus to &#147;resTORbio,&#148;
&#147;we,&#148; &#147;our,&#148; &#147;us&#148; and &#147;the Company&#148; refer, collectively, to resTORbio, Inc. and, where appropriate, our subsidiary. When we refer to &#147;you,&#148; we mean the holders of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use various trademarks and trade names in our business, including without limitation our corporate name and logo. This prospectus
supplement, the accompanying prospectus and the information incorporated herein and therein by reference contain references to trademarks, service marks and trade names owned by us or other companies. Solely for convenience, trademarks, service
marks and trade names referred to in this prospectus supplement, the accompanying prospectus and the information incorporated herein and therein, including logos, artwork, and other visual displays, may appear without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable
licensor to these trademarks, service marks and trade names. We do not intend our use or display of other companies&#146; trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other
companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement, the accompanying prospectus or any related free writing prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_2"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain and
any free writing prospects we authorize for use in connection with this offering may contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are
often, but are not always, made through the use of words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;continue,&#148; and similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements
involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them. We believe that it is important to communicate our future expectations to our investors. However, there may
be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain and any free
writing prospects we authorize for use in connection with this offering may contain forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. These statements
relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize RTB101 alone or in combination with rapalogs, such as everolimus or
sirolimus, and other product candidates for the targeted indications and patient populations, including the therapeutic potential and clinical benefits thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ongoing and future clinical trials for RTB101 alone or in combination with rapalogs, such as everolimus or
sirolimus, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the anticipated results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of acceptance and clinical utility of any products for which we receive regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional product candidates with significant commercial potential;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to enter into collaborations for the development and commercialization of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of any future collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the use of cash, cash equivalents and marketable securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected uses of the net proceeds from this offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, completely and with
the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus supplement and the documents we incorporate by reference herein represent our views as of their
respective dates. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so
except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere or incorporated by reference in this
prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all the information that you should consider before making your investment decision. You should read this entire prospectus supplement and the
accompanying prospectus carefully, especially the risks of investing in our securities discussed under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement, along with our financial
statements and related notes and the other information incorporated by reference into this prospectus supplement and the accompanying prospectus and any free writing prospectus we authorize for use in connection with this offering, before making an
investment decision. This prospectus supplement may add to, update or change information in the accompanying prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat <FONT
STYLE="white-space:nowrap">age-related</FONT> diseases with the potential to extend healthy lifespan. Our lead program selectively inhibits the target of rapamycin complex 1, or TORC1, an evolutionarily conserved pathway that contributes to the
decline in function of multiple organ systems. Our lead product candidate, RTB101, is an oral, selective, and potent inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Inhibition of TORC1 has been
observed to extend lifespan and healthspan in aging preclinical species and to enhance immune, neurologic and cardiac functions, suggesting potential benefits in several aging-related diseases. We have successfully completed a Phase 2b clinical
trial in our initial indication to reduce the incidence of respiratory tract infections, or RTIs, in the elderly regardless of the causative pathogen, and based on communications to date, including an end of Phase 2 meeting with the U.S. Food and
Drug Administration, or FDA, we plan to initiate Phase 3 clinical trials in the second quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decline in immune function
that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including RTIs, that significantly contribute to morbidity and mortality in the elderly. Our initial focus is on the development of RTB101 as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunotherapy designed to improve immune function and thereby reduce respiratory illness in the elderly regardless of the causative pathogen. Our TORC1
immunotherapy approach is supported by two randomized, placebo-controlled Phase 2 clinical trials which enrolled more than 900 elderly subjects and provided statistically significant (defined as nominal p &lt; 0.05) and clinically meaningful
results. In 2018, we reported results from our exploratory dose-ranging randomized, placebo-controlled Phase 2b clinical trial in 652 elderly patients at increased risk of <FONT STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and
mortality defined as aged 85 and over, or <FONT STYLE="white-space:nowrap">65-84</FONT> with one or more comorbidities including: asthma, chronic obstructive pulmonary disease, or COPD, type 2 diabetes mellitus, or T2DM, or current smoker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results from this trial demonstrated a statistically significant and clinically meaningful 30.6% reduction in the percentage of patients
with one or more laboratory-confirmed RTIs, the primary endpoint of the trial, in the RTB101 10 mg once daily cohort compared to the placebo cohort. Prespecified analyses of the patient populations enrolled in the trial demonstrated (i)&nbsp;a
statistically significant 52.1% reduction in the percentage of patients with severe laboratory-confirmed RTI symptoms in the RTB101 10 mg once daily cohort compared to the placebo cohort, (ii)&nbsp;a statistically significant 66.7%, 68.9%, and 25.3%
reduction in the prespecified endpoint of patients 85 and older, 65 and older with asthma and 65 and older with T2DM, respectively, with one or more laboratory-confirmed RTIs in the RTB101 10 mg once daily cohort compared to the placebo cohort, and
(iii)&nbsp;no reduction in the incidence of laboratory-confirmed RTIs in patients who were current smokers or with COPD in the RTB101 10 mg once daily cohort compared to the placebo cohort. The lack of efficacy observed in current smokers and
patients with COPD is consistent with <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data suggesting that mTOR inhibition exacerbates cigarette smoke-induced lung inflammation in COPD. The combination of RTB101+everolimus and the RTB101 10 mg
twice daily did not meet the primary endpoint, suggesting that less TORC1 inhibition with </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
RTB101 10 mg once daily may be more beneficial for reducing the incidence of RTIs in high risk elderly patients. We believe the collective results from our Phase 2a and Phase 2b clinical trials
enrolling more than 900 elderly subjects suggest that RTB101 10 mg once daily, if successfully developed and approved, may improve the function of the aging immune system and reduce the incidence of clinically symptomatic respiratory illness in
elderly patients. In our planned Phase 3 program, we expect to enroll elderly subjects 65 and older, excluding current smokers and COPD patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We observed additional positive results from prespecified analyses for any infection and urinary tract infections, or UTIs, in our Phase 2b
trial, such as (i)&nbsp;a statistically significant 23.6% reduction in the percentage of patients with any infection in the RTB101 10 mg once daily cohort compared to the placebo cohort, (ii)&nbsp;a statistically significant 74.6% reduction in the
percentage of patients with one or more UTIs in the RTB101 10 mg twice daily cohort and (iii)&nbsp;a 34.4% reduction in patients with one or more UTIs in the RTB101 10 mg once daily cohort. Recent scientific findings, including those published in
the scientific journals <I>Cell</I>, <I>Nature</I> and <I>Science</I>, suggest that aging and aging-related conditions, such as immunosenescence, may be attributable not only to random cellular wear and tear, but also to specific intra-cellular
signaling pathways, including the mTOR pathway. mTOR is a protein kinase that signals via two multiprotein complexes, known as TORC1 and TORC2. TORC1 inhibition has been observed to prolong lifespan, enhance immune function, ameliorate heart
failure, enhance memory and mobility, decrease adiposity, and delay the onset of aging-related diseases in multiple animal studies. Specifically, with respect to enhanced immune function, TORC1 inhibition was observed in preclinical studies to
rejuvenate blood, or hematopoietic, stem cell function, increase infection-fighting white blood cell production and enhance antibody-mediated, or adaptive, immunity. On the other hand, TORC2 inhibition has been observed to decrease lifespan in
preclinical studies and cause unwanted side effects of hyperlipidemia and hyperglycemia in certain animals and humans. Therefore, based on these observations and data from more than 900 patients enrolled in our Phase 2a and Phase 2b clinical trials,
we believe our TORC1 program has the potential to improve immune function and counteract immunosenescence in the elderly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reduced
ability of elderly subjects to effectively detect and fight infections is most commonly manifested in their susceptibility to RTIs and the negative effects such infections have on their overall health. RTIs are the second leading cause of
hospitalization in people age 85 and over, and the fourth leading cause in people age 65 and over, contributing to high healthcare costs that are three to five times higher than for the elderly population than for the younger population.
Furthermore, antibiotics, which are ineffective against viruses, are often prescribed indiscriminately to treat RTIs, which may cause side effects and contribute to the growing global problem of antibiotic resistance. As the elderly represent the
fastest growing population in the world, we believe there is significant unmet medical need for innovative therapeutic options for reducing the incidence of RTIs by improving the function of the aging immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our approach to addressing RTIs in the elderly possesses several clinical and commercial advantages. Our TORC1 program offers an
immunotherapy approach that has the potential to address a broad range of viral and bacterial pathogens. Statistically significant and clinically meaningful reductions in RTI incidence were observed in our Phase 2a and Phase 2b clinical trials with
RTB101 10mg once daily. We believe the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">risk-to-benefit</FONT></FONT> ratio of our program observed in clinical studies to date is well-suited to the elderly due to the following
observations: our oral product candidates were well-tolerated in elderly subjects, none of the participants in the active treatment arms experienced a serious adverse event that was related to the study drug, and the doses being investigated in our
Phase 2b clinical trial were 60 to 240 times lower than maximum tolerated doses established in prior clinical trials for other indications. Based on communications to date with the U.S. Food and Drug Administration, or FDA, including an end of Phase
2 meeting, we plan to initiate a Phase 3 clinical program in the second quarter of 2019. We plan to conduct pivotal clinical trials and to seek regulatory approval for commercialization of RTB101 in the United States and Europe. Separate pivotal
trials may be conducted to support potential approvals in Japan and China. In some markets, we may collaborate with third parties for the development and commercialization of our product candidates. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We licensed the worldwide rights to our TORC1 program, including RTB101 alone or in
combination with everolimus, from Novartis International Pharmaceutical Ltd., or Novartis, in March 2017. Our management team includes our <FONT STYLE="white-space:nowrap">co-founders,</FONT> Chen Schor, who serves as our President and Chief
Executive Officer, Joan Mannick, M.D., who serves as our Chief Medical Officer, Meredith Manning, who serves as our Chief Commercial Officer, and additional veterans in drug development and discovery, with executive experience in leading global
pharmaceutical companies. Dr.&nbsp;Mannick led the TORC1 clinical program at Novartis Institutes for Biomedical Research, Inc., or NIBR, prior to our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of the program. We are supported by investors
that include both private equity venture capital funds and public healthcare investment funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes key information about our product candidates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g723059g38y52.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For heart failure with preserved ejection fraction, and certain other infections, we may be required to file an
investigational new drug application, or IND, prior to initiating Phase 2 clinical trials. We expect to have the ability to initiate these Phase 2 clinical trials without the need to conduct prior Phase 1 clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to be a leading
biopharmaceutical company focused on treating aging-related diseases. We strive to maintain a leadership position in the TORC1 inhibitor class of pharmaceutical products for aging-related diseases. The key elements of our strategy to achieve this
goal include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Rapidly advance our TORC1 program as immunotherapy for reducing the incidence of clinically symptomatic
respiratory illness in elderly subjects</I>. In July 2018, we reported positive topline data from our Phase 2b clinical trial of RTB101 alone and in combination with everolimus in elderly subjects at increased risk of mortality and morbidity due to
RTIs. In that trial, RTB101 10 mg once daily reduced the incidence of RTI by 30.6% in the populations studied in the trial. Based on the topline results and communications to date including an end of Phase 2 meeting with the FDA, we plan to initiate
pivotal clinical trials in the second quarter of 2019 where we will study RTB101 10 mg once daily in subjects 65 years and older, excluding current smokers and COPD patients. The goal of the pivotal trials is to potentially submit an application for
regulatory approval of RTB101 in the United States, Europe and additional countries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Develop our TORC1 program for additional indications. </I>We also intend to develop RTB101, alone or in
combination with a rapalog, such as everolimus and sirolimus, for the treatment of additional aging-related diseases based on preclinical and clinical evidence on the effects of TORC1 inhibition. We believe that there is strong rationale to support
the investigation of RTB101, alone or in combination with a rapalog, for the prevention and treatment of additional aging-related indications, including other infections, for example, urinary tract infections, neurodegenerative diseases and heart
failure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Commercialize our product candidates in the United States and potentially collaborate with others globally to
maximize their commercial value</I>. We plan to directly commercialize our product candidates in the United States with a sales force mainly targeting pulmonologists and geriatricians with a high flow of patients 65 years of age and above. We may
consider collaborating with third parties to broaden the distribution of our product candidates in the United States. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue strategic
collaborations with third parties in order to maximize the commercial potential of our product candidates. We believe there are significant opportunities to market RTB101, if approved, in Europe and Japan, which we may choose to pursue in
collaboration with others. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Maintain and grow a robust intellectual property portfolio in the field of TORC1 inhibition for aging-related
diseases. </I>We have an exclusive license to ten patent families directed to compositions of matter, methods of use and formulations covering RTB101 alone or in combination with everolimus and have filed additional method of use patent
applications. We intend to aggressively pursue and maintain broad intellectual property protection for RTB101 alone or in combination with a rapalog, such as everolimus or sirolimus, or other compounds for the prevention of RTIs and the prevention
or&nbsp;treatment of other aging-related diseases through U.S. and international patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates that enhance our
global leadership position. </I>We have additional TORC1 inhibitor compounds in discovery that we may develop, and we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates targeting TORC1 and other pathways that
regulate aging to support our goal to be the leading biopharmaceutical company focused on the treatment of aging-related diseases. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
under the laws of the State of Delaware in July 2016 and commenced research and development operations in March 2017. Our principal executive offices are located at 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>
Floor, Boston, MA 02116. Our telephone number is (857) <FONT STYLE="white-space:nowrap">315-5521.</FONT> Our website is located at <I>www.restorbio.com</I>. Our website and the information contained on, or that can be accessed through, the website
will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus supplement. You should not rely on any such information in making your decision whether to purchase our common stock. Our common stock trades on
the Nasdaq Global Select Market under the symbol &#147;TORC&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our most recently completed fiscal year, we qualify as an &#147;emerging
growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and
other requirements that are otherwise applicable, in general, to public companies that are not emerging growth companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the <FONT STYLE="white-space:nowrap">non-binding</FONT> stockholder advisory votes on executive
compensation or golden parachute arrangements; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure of financial information in this prospectus supplement, such as being permitted to include
only two years of audited financial information and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; disclosure. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions for up to
five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.07&nbsp;billion in annual revenues as of the end of a fiscal year, have more than
$700&nbsp;million in market value of our capital stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of any December&nbsp;31 before that time or if we issue more than $1.0&nbsp;billion of
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year-period. We may choose to take advantage of some, but not all, of the available exemptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting
standards applicable to public companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such
standards is required for <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us: </P></TD>
<TD>7,200,000 shares (or 8,280,000 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common stock </P></TD>
<TD>We have granted the underwriters an option exercisable for 30 days from the date of this prospectus supplement to purchase up to 1,080,000 additional shares from us. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>35,255,344 shares (or 36,335,344 shares if the underwriters exercise in full their option to purchase additional shares). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $46.5&nbsp;million (or approximately $53.6&nbsp;million
if the underwriters exercise their option to purchase additional shares of common stock in full). We currently intend to use the net proceeds from this offering primarily to fund activities relating to the advancement of our product candidates, and
for other general corporate purposes, including, but not limited to, research and development costs, potential strategic acquisitions of complementary businesses, services or technologies, expansion of our technology infrastructure and capabilities,
working capital and capital expenditures. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-15</FONT> of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-11</FONT> of this prospectus supplement and under similar headings in the documents incorporated by reference into
this prospectus supplement for a discussion of the factors you should carefully consider before deciding to invest in our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;TORC&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on
28,055,344 shares outstanding as of December&nbsp;31, 2018. This number of shares excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,122,677 shares of common stock issuable upon the exercise of stock options outstanding as of December&nbsp;31,
2018 at a weighted-average exercise price of $11.63 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24,960 shares of common stock issuable upon the vesting of restricted stock units outstanding as of
December&nbsp;31, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">545,040 shares of common stock issuable upon the exercise of stock options granted subsequent to
December&nbsp;31, 2018, at a weighted-average exercise price of $8.54 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,350,582 shares of common stock reserved for future issuance under our 2018 Stock Option and Incentive Plan, or
2018 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">275,030 shares of common stock reserved for the future issuance under our 2018 Employee Stock Purchase Plan, or
2018 ESPP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,122,213 shares of common stock which become issuable under our 2018 Plan and 280,553 shares of common stock,
which became issuable under our 2018 ESPP, effective as of January&nbsp;1, 2019, pursuant to an evergreen provision contained in each of the 2018 Plan and 2018 ESPP. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any of these options are exercised, restricted stock units vest, new options are issued under our equity incentive plans and subsequently
exercised, or we issue additional shares of common stock in the future, there will be further dilution to the investors participating in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus supplement assumes that the underwriters do not exercise their option to purchase up to
1,080,000 additional shares of our common stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors described below and the risk
factors incorporated by reference to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the period ended December&nbsp;31, 2018, and any subsequent Annual Reports on Form
<FONT STYLE="white-space:nowrap">10-K,&nbsp;Quarterly</FONT> Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;or</FONT> Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;we</FONT> file after the date of this
prospectus supplement, and all other information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus, including our financial statements and the related notes, as updated by our subsequent filings
under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) and in any free writing prospectus that we have authorized for use in connection with this offering before acquiring any of our common stock. These risks could have
a material and adverse impact on our business, results of operations, financial condition and growth prospects, which may cause the trading price of our common stock to decline and you could lose all or part of your investment. The risks discussed
below also include forward-looking statements and our actual results may differ substantially from those discussed in these forward-looking statements. See &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related To This Offering and Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock historically has been volatile, which may affect the price at which you could sell any shares of our common stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The&nbsp;market price for our common stock historically has been highly volatile and could continue to be subject to wide
fluctuations in response to various factors. The market price for our common stock has varied between a high price of $20.59 on July&nbsp;25, 2018 and a low price of $6.70 on March&nbsp;19, 2019 in the twelve-month period ending on March&nbsp;19,
2019. This volatility may affect the price at which you could sell the shares of our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our stock price is likely to continue to
be volatile and subject to significant price and volume fluctuations in response to market and other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of preclinical studies or clinical trials of our product candidates or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States, or U.S., and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our product candidates or clinical development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire
<FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;additional</FONT> product candidates or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of a substantial number of shares of our common stock in the public market, or the perception in the market
that the holders of a large number of shares intend to sell shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in general, and the Nasdaq Global Select
Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price
of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against
us, could result in substantial costs and diversion of management&#146;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and
in ways that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently intend to use the net proceeds from this offering in
the manner described in the section titled &#147;Use of Proceeds&#148; in this prospectus supplement, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do
not improve our results of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use the net proceeds from this offering. The failure by our management to apply these funds
effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a
manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior at the
time of sale. As a result, investors purchasing shares of common stock in this offering will incur immediate dilution of $2.67 per share based on the public offering price of $6.95 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have a significant number of stock options outstanding. The exercise of any of these outstanding options could result in
further dilution. Further, because we expect we will need to raise additional capital to fund our future activities, we may in the future sell substantial amounts of common stock or securities convertible into or exchangeable for common
stock.<I></I>&nbsp;Future issuances of common stock or common stock-related securities, together with the exercise of&nbsp;outstanding&nbsp;stock options, if any, may result in further dilution.&nbsp;For additional information on the dilution that
you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or
rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional&nbsp;capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing
equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell
common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors
could gain rights superior to our existing stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;1, 2019, we filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-229499)</FONT> with the SEC, which was declared effective on February&nbsp;12, 2019 (the &#147;Shelf Registration Statement&#148;), in relation to the
registration of common stock, preferred stock, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, convertible securities or other equity securities in one or more
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offerings.&nbsp;The Shelf Registration Statement also registered for resale from time to time up to 12,445,646 shares of common stock held by the selling stockholders named therein. We also
simultaneously entered into a Controlled Equity Offering Sales Agreement (the &#147;Sales Agreement&#148;) with SVB Leerink LLC and Cantor Fitzgerald&nbsp;&amp; Co., (the &#147;Sales Agents&#148;), to provide for the offering, issuance and sale of
up to an aggregate amount of $50.0&nbsp;million of our common stock from time to time in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offerings under the Shelf Registration Statement and
subject to the limitations thereof.&nbsp;The Company will pay to the Sales Agent cash commissions of 3.0&nbsp;percent of the aggregate gross proceeds of sales of common stock under the Sales Agreement. Sales of common stock, convertible securities
or other equity securities by us or our stockholders under the Shelf Registration Statement may represent a significant percentage of our common stock currently outstanding. If we or our stockholders sell, or the market perceives that we or our
stockholders intend to sell, substantial amounts of our common stock under the Shelf Registration Statement or otherwise, the market price of our common stock could decline significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, sales of a substantial number of shares of our outstanding common stock in the public market could&nbsp;occur&nbsp;at any time.
These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Significant portions of these shares are held by a relatively small
number of stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders&nbsp;and management own a significant percentage of our stock and will be able to exert significant control over matters
subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;15, 2019, our executive officers, directors, five percent or greater
stockholders and their affiliates&nbsp;beneficially&nbsp;own approximately 80.9% of our outstanding voting stock. These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine
all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or
discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could depress
the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock. In
addition, the sale of substantial amounts of our common stock could adversely impact its price. As of December&nbsp;31, 2018, we had outstanding 28,055,344 shares of our common stock and options to purchase 1,122,677 shares of our common stock (of
which 67,613 were exercisable as of that date). The sale or the availability for sale of a large number of shares of our common stock in the public market could cause the price of our common stock to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and
trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend, in part, on the research and reports that
securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on us, which may negatively impact the trading price for our stock. In addition, if one or more of the
analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely
decline. If one or more of these analysts cease coverage of us or fail to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our
future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your
sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable
to emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are
applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, not being required to
comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial
statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock price may be reduced or more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take
advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may be adversely affected by market conditions affecting the stock markets in
general, including price and trading fluctuations on the Nasdaq Global Select Market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market conditions may result in volatility
in the level of, and fluctuations in, market prices of stocks generally and, in turn, our common stock and sales of substantial amounts of our common stock in the market, in each case being unrelated or disproportionate to changes in our operating
performance. Concerns over global stability and economic conditions in the U.S. and abroad have contributed to the extreme volatility of the markets, which may have an effect on the market price of our common stock<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately $46.5&nbsp;million, or approximately $53.6&nbsp;million if the
underwriters exercise in full their option to purchase additional shares of our common stock, after deducting underwriting discounts and commissions and estimated offering expenses. We currently intend to use the net proceeds of this offering
primarily to fund activities relating to the advancement of our product candidates and for other general corporate purposes including, but not limited to, research and development costs, including the conduct of one or more clinical trials and
process development and manufacturing of our product candidates, potential strategic acquisitions of complementary businesses, services or technologies, expansion of our technology infrastructure and capabilities, working capital and capital
expenditures. We have not entered into any agreements or commitments with respect to any acquisitions or investments at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based
on our current plans, we believe our cash, cash equivalents and marketable securities as of December&nbsp;31, 2018, together with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure
requirements through 2020. Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus supplement, we cannot predict with certainty all
of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly
depending upon numerous factors, including the progress of our development efforts, the status of and results from the ongoing clinical trials or any clinical trials we may commence in the future, and the scope and results of our regulatory
activities. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have
not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We intend to retain all of our future earnings, if any, to finance the
growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public
offering price per share of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering.&nbsp;Our net tangible book value as of December&nbsp;31, 2018 was approximately
$104.2&nbsp;million, or approximately $3.71 per share of common stock. Net tangible book value per share represents the amount of total tangible assets (total assets less intangible assets) less total liabilities, divided by the number of shares of
our common stock outstanding as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors participating
in this offering represents the difference between the amount per share paid by purchasers in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. After giving
effect to the sale of 7,200,000 shares of our common stock at the public offering price of $6.95 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book
value as of December&nbsp;31, 2018 would have been approximately $150.7&nbsp;million, or approximately $4.28 per share of common stock. This represents an immediate increase in net tangible book value of $0.56 per share of common stock to our
existing stockholders and an immediate dilution in net tangible book value of $2.67 per share of common stock to investors participating in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution&nbsp;per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from
the public offering price per share paid by new investors.&nbsp;The following table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors attributable to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of December&nbsp;31, 2018, after giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information above assumes that the underwriters do not exercise their option to purchase additional
shares. If the underwriters exercise in full their option to purchase an assumed 1,080,000 additional shares of common stock at the public offering price of $6.95 per share, the as adjusted net tangible book value after this offering would be $4.34
per share, representing an increase in net tangible book value of $0.63 per share to existing stockholders and immediate dilution in net tangible book value of $2.61 per share to investors purchasing our common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information above and in the foregoing table is based on 28,055,344 shares of our common stock outstanding as of December&nbsp;31, 2018,
and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,122,677 shares of common stock issuable upon the exercise of stock options outstanding as of December&nbsp;31,
2018 at a weighted-average exercise price of $11.63 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24,960 shares of common stock issuable upon the vesting of restricted stock units outstanding as of
December&nbsp;31, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">545,040 shares of common stock issuable upon the exercise of stock options granted subsequent to
December&nbsp;31, 2018, at a weighted-average exercise price of $8.54 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,350,582 shares of common stock reserved for future issuance under our 2018 Stock Option and Incentive Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">275,030 shares of common stock reserved for the future issuance under our 2018 Employee Stock Purchase Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,122,213 shares of common stock which become issuable under our 2018 Plan and 280,553 shares of common stock,
became issuable under our 2018 ESPP effective as of January&nbsp;1, 2019, pursuant to an evergreen provision contained in each of the 2018 Plan and 2018 ESPP. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may choose to raise additional capital in the future through the sale of equity or convertible debt securities due to market
conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that any of our outstanding options are exercised, new options are issued under our equity incentive plans
or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS <FONT
STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.&nbsp;HOLDERS</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The&nbsp;following discussion is a summary of certain material U.S.
federal income tax considerations <FONT STYLE="white-space:nowrap">for&nbsp;non-U.S.&nbsp;holders&nbsp;(as</FONT> defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For
purposes of this <FONT STYLE="white-space:nowrap">discussion,&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;means</FONT> a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">a&nbsp;non-resident&nbsp;alien&nbsp;individual;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax
purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for
U.S. federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax
advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing
and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus supplement and all of which are subject to change or to differing
interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax <FONT STYLE="white-space:nowrap">consequences&nbsp;to&nbsp;non-U.S.&nbsp;holders&nbsp;described</FONT> in this prospectus supplement.
There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion
<FONT STYLE="white-space:nowrap">that&nbsp;a&nbsp;non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to
<FONT STYLE="white-space:nowrap">a&nbsp;particular&nbsp;non-U.S.&nbsp;holder&nbsp;in</FONT> light <FONT STYLE="white-space:nowrap">of&nbsp;that&nbsp;non-U.S.&nbsp;holder&#146;s&nbsp;individual</FONT> circumstances nor does it address U.S. state, <FONT
STYLE="white-space:nowrap">local&nbsp;or&nbsp;non-U.S.&nbsp;taxes,&nbsp;the</FONT> alternative minimum tax, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code, the Medicare tax on net investment
income or any other aspect of any U.S. federal tax other than the income tax. This discussion also does not consider any specific facts or circumstances that may apply
<FONT STYLE="white-space:nowrap">to&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;and</FONT> does not address the special tax rules applicable <FONT STYLE="white-space:nowrap">to&nbsp;particular&nbsp;non-U.S.&nbsp;holders,&nbsp;such</FONT> as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;or&nbsp;governmental</FONT> organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(I)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our
common stock being taken into account in an applicable financial statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax advice. Accordingly, all prospective
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax&nbsp;consequences of the ownership
and disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the &#147;Risk Factors&#148; section above, we do not anticipate paying any cash dividends on our capital stock in the
foreseeable future. Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as&nbsp;a&nbsp;tax-free&nbsp;return&nbsp;of&nbsp;the&nbsp;non-U.S.&nbsp;holder&#146;s&nbsp;investment,</FONT></FONT> up to such holder&#146;s tax basis in the common stock. Any
remaining excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; Any such distributions will also be subject to the discussions below under
the sections titled &#147;Backup Withholding and Information Reporting&#148; and &#147;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion in the
following two paragraphs in this section, dividends paid <FONT STYLE="white-space:nowrap">to&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;generally</FONT> will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. Dividends that are treated as effectively connected with a trade or business conducted
<FONT STYLE="white-space:nowrap">by&nbsp;a&nbsp;non-U.S.&nbsp;holder</FONT> within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained <FONT
STYLE="white-space:nowrap">by&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;within</FONT> the United&nbsp;States, are generally exempt from the 30% withholding tax
<FONT STYLE="white-space:nowrap">if&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;satisfies</FONT> applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at
the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received <FONT STYLE="white-space:nowrap">by&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;that</FONT> is a
corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s
country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A&nbsp;non-U.S.&nbsp;holder&nbsp;of</FONT> our common stock who claims the benefit
of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;or&nbsp;W-8BEN-E&nbsp;(or&nbsp;successor</FONT></FONT></FONT> form) to the applicable withholding agent and satisfy applicable certification and
<FONT STYLE="white-space:nowrap">other&nbsp;requirements.&nbsp;Non-U.S.&nbsp;holders&nbsp;are</FONT> urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax
<FONT STYLE="white-space:nowrap">treaty.&nbsp;A&nbsp;non-U.S.&nbsp;holder&nbsp;that</FONT> is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely
filing a U.S. tax return with the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#147;Backup Withholding and Information Reporting&#148; and
<FONT STYLE="white-space:nowrap">&#147;FATCA,&#148;&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;generally</FONT> will not be subject to any U.S. federal income or withholding tax on any gain realized upon such holder&#146;s sale or other taxable
disposition of shares of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected
<FONT STYLE="white-space:nowrap">with&nbsp;the&nbsp;non-U.S.&nbsp;holder&#146;s&nbsp;conduct</FONT> of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base
maintained <FONT STYLE="white-space:nowrap">by&nbsp;such&nbsp;non-U.S.&nbsp;holder&nbsp;in</FONT> the United States, in which <FONT STYLE="white-space:nowrap">case&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;generally</FONT> will be taxed on a net
income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, <FONT STYLE="white-space:nowrap">if&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;is</FONT> a foreign corporation, the branch
profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;non-U.S.&nbsp;holder&nbsp;is</FONT> a nonresident alien individual who
is present in the United States for 183 days or more in the taxable year of the disposition and&nbsp;certain other conditions are met, in which <FONT STYLE="white-space:nowrap">case&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;will</FONT> be subject to a
30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source
capital losses <FONT STYLE="white-space:nowrap">of&nbsp;the&nbsp;non-U.S.&nbsp;holder,&nbsp;if</FONT> any (even though the individual is not considered a resident of the United States), provided
<FONT STYLE="white-space:nowrap">that&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;has</FONT> timely filed U.S. federal income tax returns with respect to such losses; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition <FONT
STYLE="white-space:nowrap">(or&nbsp;the&nbsp;non-U.S.&nbsp;holder&#146;s</FONT> holding period, if shorter) a U.S. real property holding corporation, unless our common stock is regularly traded on an established securities market <FONT
STYLE="white-space:nowrap">and&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;holds</FONT> no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter
<FONT STYLE="white-space:nowrap">of&nbsp;the&nbsp;5-year&nbsp;period&nbsp;ending</FONT> on the date of the disposition or the period <FONT STYLE="white-space:nowrap">that&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;held</FONT> our common stock.
Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other
assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be
provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and <FONT STYLE="white-space:nowrap">to&nbsp;each&nbsp;non-U.S.&nbsp;holder&nbsp;the</FONT> gross amount of
the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such <FONT STYLE="white-space:nowrap">distributions.&nbsp;Non-U.S.&nbsp;holders</FONT> may have to comply with specific certification procedures
to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends
<FONT STYLE="white-space:nowrap">paid&nbsp;to&nbsp;non-U.S.&nbsp;holders&nbsp;subject</FONT> to withholding of U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup
withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock <FONT
STYLE="white-space:nowrap">by&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;effected</FONT> by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status
<FONT STYLE="white-space:nowrap">as&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;and</FONT> satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of
disposition proceeds <FONT STYLE="white-space:nowrap">to&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;where</FONT> the transaction is effected outside the United States
<FONT STYLE="white-space:nowrap">through&nbsp;a&nbsp;non-U.S.&nbsp;office&nbsp;of</FONT> a broker. However, for information reporting purposes, dispositions effected through <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;office&nbsp;of</FONT>
a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a&nbsp;broker.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;holders&nbsp;should</FONT> consult their tax
advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in
<FONT STYLE="white-space:nowrap">which&nbsp;the&nbsp;non-U.S.&nbsp;holder&nbsp;resides</FONT> or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the
backup withholding rules from a payment <FONT STYLE="white-space:nowrap">to&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;can</FONT> be refunded or credited <FONT STYLE="white-space:nowrap">against&nbsp;the&nbsp;non-U.S.&nbsp;holder&#146;s&nbsp;U.S.</FONT>
federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding
tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting,
withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise
exempt under FATCA. Such withholding may also apply to gross proceeds from the sale or other disposition of our common stock, although under recently proposed U.S. Treasury Regulations, no withholding would apply to such gross proceeds. The preamble
to the proposed regulations specifies that taxpayers (including withholding agents) are permitted to rely on the proposed regulations pending finalization. Under certain
<FONT STYLE="white-space:nowrap">circumstances,&nbsp;a&nbsp;non-U.S.&nbsp;holder&nbsp;may</FONT> be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country
may modify the requirements described in <FONT STYLE="white-space:nowrap">this&nbsp;paragraph.&nbsp;Non-U.S.&nbsp;holders&nbsp;should</FONT> consult their tax advisors regarding the possible implications of this legislation on their investment in
our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_8a"></A>DESCRIPTION OF&nbsp;CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of our common stock and preferred stock summarizes the material terms and provisions of the common stock that we
may offer under this prospectus supplement. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our amended and restated certificate of incorporation and restated bylaws
and by applicable law. The terms of our common stock and preferred stock may also be affected by Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our&nbsp;authorized capital stock consists of&nbsp;150,000,000&nbsp;shares of common stock, par value $0.0001 per share,
and&nbsp;10,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As&nbsp;of March&nbsp;19, 2019, 28,055,344 shares of our common stock were outstanding and held by 7 stockholders of record. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The&nbsp;holders of our
common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably
any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other
subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In&nbsp;the event of our liquidation, dissolution or winding up, holders of
our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.&nbsp;All outstanding shares are fully paid and
nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we issue shares of common stock under this prospectus supplement, the shares will fully be paid and nonassessable and
will not have, or be subject to, any preemptive or similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Undesignated Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our&nbsp;board of directors is authorized to issue up to&nbsp;10,000,000&nbsp;shares of undesignated preferred stock in one or more series
without stockholder approval.&nbsp;Our board of directors may determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each
series of preferred stock.&nbsp;The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with a
stockholder vote on specific issuances. Examples of rights and preferences that the board of directors may fix are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dividend rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terms of redemption; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation preference; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sinking fund terms; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares constituting, or the designation of, such series, any or all of which may be greater than
the rights of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of authorized but unissued shares of undesignated preferred stock may enable
our board of directors to&nbsp;discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine
that a takeover proposal is not in the&nbsp;best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that
might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group.&nbsp;The rights of holders of our common stock described above, will be subject to, and may be adversely affected by, the rights of any preferred
stock that we may designate and issue in the future. The issuance&nbsp;of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also
adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant&nbsp;to the
terms of our investors&#146; rights agreement entered into in November 2017, certain of our stockholders are entitled to rights with respect to the registration of their shares under the Securities Act until the earliest of (a)&nbsp;January 2023,
(b) the date on which such holder ceases to hold registrable securities, or (c)&nbsp;such holder&#146;s registrable securities could be sold without any restriction on volume or manner of sale on any three-month period under Rule 144 or any
successor rule, as described below. We refer to these shares collectively as registrable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;holders of&nbsp;2,021,237 shares of our common stock are entitled to demand registration rights. Under the terms of the investors&#146; rights
agreement, we will be required, upon the written request of the holders of at least 20% of our outstanding registrable securities, as defined in the investors&#146; rights agreement, to file&nbsp;a registration statement with respect to at least 40%
of the registrable securities and use commercially reasonable efforts to effect the registration of all or a portion of their registrable securities for public resale so long as the total amount of registrable shares requested to be registered has
an anticipated aggregate offering price to the public, net of selling expenses, of at least $15.0&nbsp;million. We are required to effect only two registrations pursuant to this provision of the investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Short-Form Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of at least 10% of our outstanding registrable securities can request that we register all or part of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file&nbsp;a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and if the aggregate offering price, net of selling expenses, is at least $10.0&nbsp;million. We are required to effect only two registrations in any twelve month period pursuant to the investors&#146;
rights agreement. The right to have such shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to
certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion
will not jeopardize the success of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_9"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and SVB Leerink LLC are acting as representatives of the underwriters. We have
entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public
offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,448,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all the common shares offered by us if they purchase any shares.
The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the common shares directly to the public at the initial public offering price set forth on the cover page of
this prospectus supplement and to certain dealers at that price less a concession not in excess of $0.2502&nbsp;per share. After the initial offering of the shares to the public, the offering price and other selling terms may be changed by the
underwriters. Sales of shares made outside of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an
option to buy up to 1,080,000 additional shares of common stock from us. The underwriters have 30&nbsp;days from the date of this prospectus supplement to exercise this option to purchase additional shares. If any shares are purchased with this
option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares
on the same terms as those on which the shares are being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting fee is equal to the public offering price per share of
common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $0.417&nbsp;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the
underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;option&nbsp;to<BR>purchase&nbsp;additional<BR>shares exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;full&nbsp;option&nbsp;to<BR>purchase&nbsp;additional<BR>shares exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$0.417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$0.417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,002,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,452,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, including registration, filing and listing fees,
printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $500,000. We have agreed to reimburse the underwriters in an amount of up to $30,000 for certain expenses incurred in
connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the web sites maintained by one
or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders have agreed, subject to certain exceptions, not to sell or
transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 90 days after the date hereof without first obtaining the written consent of the representatives. Specifically, we and
these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file a registration statement related to the common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership
of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible into or exchangeable or
exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TORC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and
selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the
common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short
sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short
positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this
determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A
naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the
representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in
the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time.
The underwriters may carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making
transactions in our common stock on the Nasdaq Stock Market prior to the pricing and completion of this offering. Passive market making consists of displaying bids on the Nasdaq Stock Market no higher than the bid prices of independent market makers
and making purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker&#146;s
average daily trading volume in the common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in
the open market in the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities
offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed
or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform
themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered
by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and
their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary
course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the
account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus supplement does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations
Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement contains general information only and does not take account of the investment objectives, financial situation or
particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus supplement is
appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited
investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (<B>NI <FONT STYLE="white-space:nowrap">33-105</FONT></B>), the
underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#147;DFSA&#148;). This prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for the prospectus
supplement. The shares to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not
understand the contents of this prospectus supplement you should consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of ordinary shares which are the subject of the offering has been, or
will be made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Directive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), subject to obtaining the prior consent of the Representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of ordinary shares referred to in (a)&nbsp;to (c) above shall result in a requirement for the Company or any Representative
to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of ordinary shares is made or who receives any communication in respect of an offer of
ordinary shares, or who initially acquires any ordinary shares will be deemed to have represented, warranted, acknowledged and agreed to and with each Representative and the Company that (1)&nbsp;it is a &#147;qualified investor&#148; within the
meaning of the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any ordinary shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the Prospectus
Directive, the ordinary shares acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is defined
in the Prospectus Directive, or in circumstances in which the prior consent of the Representatives has been given to the offer or resale; or where ordinary shares have been acquired by it on behalf of persons in any Member State other than qualified
investors, the offer of those ordinary shares to it is not treated under the Prospectus Directive as having been made to such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the Representatives and their respective affiliates will rely upon the truth and accuracy of the foregoing representations,
acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement has been prepared on the basis that any offer of shares in any Member State
will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the subject
of the offering contemplated in this prospectus supplement may only do so in circumstances in which no obligation arises for the Company or any of the Representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive in
relation to such offer. Neither the Company nor the Representatives have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the Representatives to publish a
prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of ordinary shares to the public&#148; in
relation to any ordinary shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the ordinary shares to be offered so as to enable an investor to decide to purchase or
subscribe the ordinary shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and
includes any relevant implementing measure in each Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies
Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the
possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities
laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules
made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares
or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other
offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be
supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection
afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in the United Kingdom </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only
at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article
19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling
within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the
United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters relating to the shares of common stock offered hereby will be passed upon for us by Goodwin Procter LLP, Boston,
Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of resTORbio, Inc. and its subsidiary as of December&nbsp;31, 2018 and 2017 and for the years ended
December&nbsp;31, 2018 and 2017, and for the period July 5, 2016 (inception) through December 31, 2016 have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered
public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_12">
</A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to the shares of common stock offered by this prospectus supplement. This prospectus supplement does not contain all the information set forth in the registration statement
and its exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. You should read the registration statement and its exhibits and schedules carefully for provisions that may be important to
you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC also maintains a website
at www.sec.gov that contains periodic and current reports, proxy and information statements, and other information regarding registrants that are filed electronically with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These documents are also available, free of charge, through the Investors section of our website, which is located at www.restorbio.com.
Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus and you should not consider information on our website to be part of this prospectus supplement or the accompanying
prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc723059_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it into our registration statement of which this
prospectus supplement is a part, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we
file later with the SEC will automatically update and supersede the information already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make
with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any future report or document that is not deemed filed under such provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018,
filed with the SEC on March&nbsp;18, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part III of our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended
December&nbsp;31, 2017, which was filed with the SEC on March&nbsp;29, 2018, as amended on April&nbsp;2, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on August&nbsp;15,
2018 (only with respect to Item 5.02), September&nbsp;18, 2018 (only with respect to Item 5.02), November&nbsp;6, 2018 (only with respect to Item 5.02) and March&nbsp;18, 2019 (except for information contained therein which is furnished rather than
filed); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-A&nbsp;filed</FONT> with the SEC on January&nbsp;22, 2018 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-28259)</FONT> under Section&nbsp;12(b) of the Exchange Act, including any amendments or
reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, and any exhibits
we have specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by writing us at the following address: Investor Relations Department, resTORbio, Inc., 500 Boylston Street, 12<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116, telephone (857) <FONT STYLE="white-space:nowrap">315-5521.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at www.sec.gov or on our website at www.restorbio.com. The
information contained on, or that can be accessed through, our website does not constitute part of this prospectus supplement, and the reference to our website address is included in this prospectus supplement as an inactive textual reference only.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g723059g23a75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$175,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>12,445,646 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time issue,
in one or more series or classes, up to $175,000,000 in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, selling stockholders named in this prospectus may from time to time offer and sell up to an aggregate of 12,445,646 shares of our common stock in
one or more offerings, subject to market conditions and prices, liquidity objectives and other investment considerations. We will not receive any of the proceeds from the sale of our common stock by the selling stockholders. We have borne and will
continue to bear the costs relating to registration of these shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer these securities separately or together in units. Each time we sell
securities described herein, and in certain cases where one or more selling stockholders sell securities pursuant to this prospectus, we or the selling stockholders, as applicable, will provide prospective investors with a supplement to this
prospectus that will specify the terms of the securities being offered. We may sell these securities to or through underwriters and also to other purchasers or through agents. We will set forth the names of any underwriters or agents, and any fees,
conversions, or discount arrangements, in the accompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. You should read this document and any prospectus
supplement or amendment carefully before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol
&#147;TORC.&#148; On January&nbsp;31, 2019, the closing price for our common stock, as reported on The Nasdaq Global Select Market, was $8.88 per share. Our principal executive offices are located at 500 Boylston Street, 12<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, Massachusetts 02116. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#toc723059_2">Risk Factors</A>&#148; contained in this prospectus beginning on page 2 and any applicable prospectus
supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this Prospectus is&nbsp;February 12, 2019 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_3">Cautionary Statement Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_4">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_6">Securities We May Offer or That a Selling Stockholder May
Offer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_7">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_8">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_9">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_10">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_11">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_12">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_15">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc723059_16">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate initial offering price of up to
$175,000,000. In addition, the selling stockholders may from time to time sell up to an aggregate amount of 12,445,646, shares of our common stock in one or more offerings, subject to market conditions and prices, liquidity objectives and other
investment considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we or the selling stockholders may
offer. Each time we sell securities described herein, and in certain cases where one or more selling stockholders sell securities pursuant to this prospectus, we or the selling stockholders, as applicable, will provide one or more prospectus
supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and the accompanying
prospectus supplement together with the additional information described under the heading &#147;Where You Can Find More Information&#148; beginning on page <B></B>of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement
or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and the accompanying prospectus supplement do not constitute an offer to sell or the
solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or
solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates.
Our business, financial condition, results of operations and prospects may have changed materially since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context
otherwise indicates, references in this prospectus to &#147;resTORbio&#148;, &#147;we&#148;, &#147;our&#148;, &#147;us&#148; and &#147;the Company&#148; refer, collectively, to resTORbio, Inc. and, where appropriate, our subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully consider the risks referenced below and described in the
documents incorporated by reference in this prospectus and any applicable prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an
investment decision. Our business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any
of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially
from those anticipated in these forward-looking statements as a result of certain factors, including the risks described below and in the documents incorporated herein by reference, including (i)&nbsp;our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, as amended, which is on file with the SEC and is incorporated herein by reference, (ii)&nbsp;our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2018, June&nbsp;30, 2018 and September&nbsp;30, 2018, which are on file with the SEC and are incorporated herein by reference and (iii)&nbsp;other documents we file
with the SEC that are deemed incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_3"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;could,&#148;
&#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;continue,&#148; and
similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them.
Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus, and in particular those factors referenced in the section &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that are based on our management&#146;s belief and assumptions and on information
currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to,
statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize RTB101 alone or in combination with rapalogs, such as everolimus or
sirolimus, and other product candidates for the targeted indications and patient populations, including the therapeutic potential and clinical benefits thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ongoing and future clinical trials for RTB101 alone or in combination with rapalogs, such as everolimus or
sirolimus, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the anticipated results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional product candidates with significant commercial potential;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to enter into collaborations for the development and commercialization of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of any future collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the use of cash, cash equivalents and marketable securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our
Business Startups Act of 2012, as amended, or the JOBS Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected uses of the net proceeds from any offering of our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference also contain estimates,
projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general
publications, government data and similar sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we incorporate by reference in
this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus and the documents we incorporate by reference herein represent
our views as of their respective dates. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_4"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing a new class of innovative medicines that target the biology of aging to prevent
or treat <FONT STYLE="white-space:nowrap">age-related</FONT> diseases with the potential to extend healthy lifespan. Our lead program is selectively targeting the target of rapamycin complex 1, or TORC1, an evolutionarily conserved pathway that
contributes to the decline in function of multiple organ systems. Our lead product candidate, RTB101, is an oral, selective, and potent inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Inhibition of
TORC1 has been observed to extend lifespan and healthspan in aging preclinical species and to enhance immune, neurologic and cardiac functions, suggesting potential benefits in several aging-related diseases. We licensed the worldwide rights to our
TORC1 program, including RTB101 alone or in combination with rapalogs, such as everolimus, sirolimus, or other mTOR inhibitors, from Novartis International Pharmaceutical Ltd. in March 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including
respiratory tract infections, or RTIs, that significantly contribute to morbidity and mortality in the elderly. Our initial focus is on the development of RTB101 as a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunotherapy designed to improve immune function and thereby reduce the incidence of RTIs in the elderly regardless of the causative pathogen. Our TORC1
immunotherapy approach is supported by two randomized, placebo-controlled Phase 2a and Phase 2b clinical trials enrolling more than 900 elderly subjects that provided statistically significant and clinically meaningful results. In 2018, we reported
results from our exploratory dose-ranging randomized, placebo-controlled Phase 2b clinical trial in 652 elderly patients at increased risk of <FONT STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and mortality defined as aged 85 and over,
or <FONT STYLE="white-space:nowrap">65-84</FONT> with one or more of comorbidities including: asthma, chronic obstructive pulmonary disease, or COPD, type 2 diabetes mellitus, or T2DM, or current smoker. The results from this trial demonstrated a
statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed RTIs, the primary endpoint of the trial, in the RTB101 10 mg once daily cohort compared to the placebo cohort.
Prespecified analyses of the patient populations enrolled in the trial demonstrated (i)&nbsp;a statistically significant 52.1% reduction in percentage of patients with severe laboratory-confirmed RTI symptoms in the RTB101 10 mg once daily cohort
compared to the placebo cohort, (ii)&nbsp;a statistically significant 66.7%, 68.9%, and 25.3% reduction in the prespecified endpoint of percentage patients 85 and older, 65 and older with asthma and 65 and older with T2DM, respectively, with one or
more laboratory-confirmed RTIs in the RTB101 10 mg once daily cohort compared to the placebo cohort, and (iii)&nbsp;no reduction in the incidence of laboratory-confirmed RTIs in patients who were current smokers or with COPD in the RTB101 10 mg once
daily cohort compared to the placebo cohort. The lack of efficacy observed in current smokers and patients with COPD is consistent with nonclinical data suggesting that mTOR inhibition exacerbates cigarette smoke-induced lung inflammation in COPD.
The combination of RTB101+everolimus did not meet the primary endpoint suggesting that less TORC1 inhibition with RTB101 10 mg once daily may be more beneficial for reducing the incidence of RTIs in high risk elderly patients. We believe the
collective results from our Phase 2a and Phase 2b clinical trials enrolling more than 900 elderly subjects suggest that RTB101 10 mg once daily may improve the function of the aging immune system and reduce the incidence of laboratory-confirmed RTIs
in elderly patients. In our planned Phase 3 studies, we may enroll elderly subjects 65 and older, excluding current smokers and COPD patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional positive results from prespecified analyses for any infection and urinary tract infections, or UTIs, from our Phase 2b trial
demonstrated (i)&nbsp;a statistically significant 23.6% reduction in the percentage of patients with any infection in the RTB101 10 mg once daily cohort compared to the placebo cohort, (ii)&nbsp;a statistically significant 74.6% reduction in the
percentage of patients with one or more UTIs in the RTB101 10 mg twice daily cohort and (iii)&nbsp;a 34.4% reduction in the percentage of patients with one or more UTIs in the RTB101 10 mg once daily cohort. If not otherwise specified, we used a
nominal 5% or lower <FONT STYLE="white-space:nowrap">p-value</FONT> (p &lt; 0.05) to define statistical significance for the clinical trials and data presented in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2019, one family in this patent portfolio covering compositions of matter has 44 issuances in 33 countries, and is
pending in six. Our issued patents and pending applications with respect to RTB101 are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected to expire in 2031 or 2032, depending on eligibility for patent term extension or supplementary protection. Additional pending applications are expected to expire between 2034 and 2037,
exclusive of possible patent term adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent scientific findings, including those published in the scientific
journals <I>Cell</I>, <I>Nature</I> and <I>Science</I>, suggest that aging and aging-related conditions, such as immunosenescence, may be attributable not only to random cellular wear and tear, but also to specific intra-cellular signaling pathways,
including the mTOR pathway. mTOR is a protein kinase that signals via two multiprotein complexes, known as TORC1 and TORC2. TORC1 inhibition has been observed to prolong lifespan, improve immune, neurologic, and cardiac function, decrease adiposity,
and delay the onset of aging-related diseases in multiple animal studies. Specifically, with respect to improved immune function, TORC1 inhibition was observed in preclinical and clinical studies to rejuvenate blood, or hematopoietic stem cell
function, increase infection-fighting white blood cell production, enhance rapid and independent of antigen, or innate immunity, and enhance antibody-mediated, or adaptive immunity. On the other hand, TORC2 inhibition has been observed to decrease
lifespan in preclinical studies and cause unwanted side effects of hyperlipidemia and hyperglycemia in certain animals and humans. Therefore, based on these observations and data from more than 900 patients enrolled in the Phase 2a and Phase 2b
clinical trials, we believe our TORC1 program has the potential to improve the function of several aging organ systems such as immune system function and counteract immunosenescence in the elderly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reduced ability of elderly patients to effectively detect and fight infections is most commonly manifested in their susceptibility to RTIs
and the negative effects such infections have on their overall health. RTIs are the second leading cause of hospitalization in people age 85 and over, and the fourth leading cause in people age 65 and over, contributing to high healthcare burdens
and costs for the elderly population and the healthcare system that are three to five times higher than for the younger population. Furthermore, antibiotics, which are ineffective against viruses, are often prescribed indiscriminately to treat RTIs,
which may cause side effects related to antibiotic use and contribute to the growing global problem of antibiotic resistance. As the elderly represent the fastest growing population in the world, we believe there is significant unmet medical need
for innovative therapeutic options for reducing the incidence of RTIs by improving the function of the aging immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe
our approach to addressing RTIs in the elderly possesses several clinical and commercial advantages. Our TORC1 program offers an immunotherapy approach that has the potential to address a broad range of viral and bacterial pathogens. Statistically
significant and clinically meaningful reductions in RTI incidence were observed in the Phase 2a and Phase 2b clinical trials with RTB101. We believe the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">risk-to-benefit</FONT></FONT>
ratio of our program observed in clinical studies to date would be well-suited to the elderly due to the following observations: our oral product candidates were well-tolerated in elderly subjects and none of the participants in the active treatment
arms experienced a serious adverse event that was related to the study drug, and the doses being investigated in our Phase 2b clinical trial were 60 to 240 times lower than maximum tolerated doses established in prior clinical trials for other
indications. Based on communications during a high-level policy meeting with the U.S. Food and Drug Administration, we believe a reduction in the incidence of RTIs has the potential to be a clinically relevant endpoint. Based on the results from our
Phase 2b clinical trial with respect to reduction in RTI incidence, we plan to conduct pivotal clinical trials and to seek regulatory approval for commercialization of RTB101 in the United States, Europe and Japan. In some markets, we may
collaborate with third parties for the development and commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team includes Chen
Schor, our <FONT STYLE="white-space:nowrap">co-founder</FONT> who serves as our President and Chief Executive Officer, and Joan Mannick, M.D., our <FONT STYLE="white-space:nowrap">co-founder</FONT> who serves as our Chief Medical Officer, Meredith
Manning, who serves as our Chief Commercial Officer, and additional veterans in drug development and discovery with executive experience in leading global pharmaceutical companies. Dr.&nbsp;Mannick led the TORC1 clinical program at Novartis
Institutes for Biomedical Research, Inc. prior to our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of the program. We are supported by investors that include both private equity venture capital funds and public healthcare investment funds.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We would cease to be an emerging growth company on the date that is the earliest of:
(i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2023; (iii) the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the
previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of Delaware in July 2016 under the name resTORbio, Inc. Our principal executive offices are located at 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116.
Our telephone number is <FONT STYLE="white-space:nowrap">(857)&nbsp;315-5521,</FONT> and our website is located at www.restorbio.com. No portion of our website is incorporated by reference into this prospectus. We do not incorporate the information
on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. Our common stock trades on The Nasdaq Global Select Market under the
symbol &#147;TORC&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use various trademarks and trade names in our business, including without limitation our corporate name and
logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless
otherwise indicated in the applicable prospectus supplement. General corporate purposes may include research and development costs, including the conduct of one or more clinical trials and process development and manufacturing of our product
candidates, potential strategic acquisitions of complementary businesses, services or technologies, expansion of our technology infrastructure and capabilities, working capital, capital expenditures and other general corporate purposes. We may
temporarily invest the net proceeds in a variety of capital preservation instruments, including investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have not determined the
amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. We will not receive any proceeds from the sale of shares of our common stock by the selling
stockholders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_6"></A>SECURITIES WE MAY OFFER OR THAT A SELLING STOCKHOLDER MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be
complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. In addition, the selling stockholders may sell from time to time up to an aggregate of 12,445,646 shares of our
common stock in one or more offerings, subject to market conditions and prices, liquidity objectives and other investment considerations. This prospectus provides you with a general description of the securities we and the selling stockholders may
offer.&nbsp;Each time we sell securities described herein, and in certain cases where one or more selling stockholders sell securities pursuant to this prospectus, we or the selling stockholders, as applicable, will provide prospective investors
with a supplement to this prospectus that will contain specific information about the terms of that offering, including the specific amounts, prices and terms of the securities offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or the selling stockholders may sell the securities to or through underwriters, dealers or agents, directly to purchasers or through a
combination of any of these methods of sale or as otherwise set forth below under &#147;Plan of Distribution.&#148; We and the selling stockholders, as well as any agents acting on our or their behalf, reserve the sole right to accept and to reject
in whole or in part any proposed purchase of securities. Any prospectus supplement will set forth the names of any underwriters, dealers, agents or other entities involved in the sale of securities described in that prospectus supplement and any
applicable fee, commission or discount arrangements with them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of our common stock and preferred stock, together with the additional information we include in any applicable
prospectus supplements, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. The following description of our capital stock does not purport to be complete and is subject to,
and qualified in its entirety by, our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. The terms of our common stock and preferred stock may also
be affected by Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of&nbsp;150,000,000&nbsp;shares of common stock, par value $0.0001 per share,
and&nbsp;10,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2019, 28,055,344 shares of our common stock were outstanding and held by 7 stockholders of record. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any
dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other
subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our
common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we issue shares of common stock under this prospectus, the shares will fully be paid and nonassessable and will not have, or be subject
to, any preemptive or similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Undesignated Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. Our board of directors may determine the rights,
preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. These rights, preferences and privileges could include
dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of
common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. The purpose of authorizing
our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. In addition, the
issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. When we issue shares of preferred stock under this prospectus, the shares will fully be paid and
nonassessable and will not be subject to any preemptive or similar rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of authorized but unissued shares of preferred
stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of
directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or
stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock
could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of
delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our investors&#146; rights agreement entered into in November 2017, certain of our stockholders are entitled to rights
with respect to the registration of their shares under the Securities Act until the earliest of (a)&nbsp;January 2023, (b) the date on which such holder ceases to hold registrable securities, or (c)&nbsp;such holder&#146;s registrable securities
could be sold without any restriction on volume or manner of sale on any three-month period under Rule 144 or any successor rule, as described below. We refer to these shares collectively as registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders
of&nbsp;14,466,883 shares of our common stock, including the 12,445,646 shares of common stock to be registered pursuant to this Registration Statement, are entitled to demand registration rights. Under the terms of the investors&#146; rights
agreement, we will be required, upon the written request of the holders of at least 20% of our outstanding registrable securities, as defined in the investors&#146; rights agreement, to file&nbsp;a registration statement with respect to at least 40%
of the registrable securities and use commercially reasonable efforts to effect the registration of all or a portion of their registrable securities for public resale so long as the total amount of registrable shares requested to be registered has
an anticipated aggregate offering price to the public, net of selling expenses, of at least $15.0&nbsp;million. We are required to effect only two registrations pursuant to this provision of the investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Short-Form Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of at least 10% of our outstanding registrable securities can request that we register all or part of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file&nbsp;a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and if the aggregate offering price, net of selling expenses, is at least $10.0&nbsp;million. We are required to effect only two registrations in any twelve month period pursuant to the investors&#146;
rights agreement. The right to have such shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to
certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion
will not jeopardize the success of the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expiration of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand registration rights and short form registration rights granted under the investors&#146; rights agreement will terminate on the
earliest of (a)&nbsp;January 2023, (b) the date on which such holder ceases to hold registrable securities, or (c)&nbsp;such holder&#146;s registrable securities could be sold without any restriction on volume or manner of sale on any three-month
period under Rule 144 or any successor rule, as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or
preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
<FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and
Filling Vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the division of our board of directors into three classes serving
staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of
<FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the
size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of
vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of
Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of
our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call
special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of
stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as
directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be
taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify
the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our
certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment
of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote
of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, or, if our board of
directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our
behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to
any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; or (4)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our certificate of incorporation also provides
that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the
choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly
held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The Nasdaq Global Select Market under the symbol &#147;TORC.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
250 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) <FONT STYLE="white-space:nowrap">962-4284.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series
of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate
whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer senior or subordinated debt securities. Each series of debt securities may have different terms. The senior debt securities will
be issued under one or more senior indentures, dated as of a date prior to such issuance, between us and the trustee identified in the applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such
indenture throughout this prospectus as the &#147;senior indenture.&#148; Any subordinated debt securities will be issued under one or more separate indentures, dated as of a date prior to such issuance, between us and the trustee identified in the
applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such indenture throughout this prospectus as the &#147;subordinated indenture&#148; and to the trustee under the senior or subordinated indenture as
the &#147;trustee.&#148; The senior indenture and the subordinated indenture are sometimes collectively referred to in this prospectus as the &#147;indentures.&#148; The indentures will be subject to and governed by the Trust Indenture Act of 1939,
as amended. We included copies of the forms of the indentures as exhibits to our registration statement and they are incorporated into this prospectus by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price
of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have summarized below the material provisions of the indentures and the debt securities, or indicated which material provisions will be
described in the related prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the general terms summarized in
this prospectus. Because the summary in this prospectus and in any prospectus supplement does not contain all of the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus
or in any applicable prospectus supplement. Please read &#147;Where You Can Find More Information&#148; to find out how you can obtain a copy of those documents. Except as otherwise indicated, the terms of the indentures are identical. As used under
this caption, the term &#147;debt securities&#148; includes the debt securities being offered by this prospectus and all other debt securities issued by us under the indentures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not limit the amount of debt securities that we may issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to issue debt securities in one or more series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not require us to issue all of the debt securities of a series at the same time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to reopen a series to issue additional debt securities without the consent of the holders of the debt
securities of such series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the debt securities will be unsecured, except as may be set forth in the applicable prospectus
supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we give you different information in the applicable prospectus supplement, the senior debt
securities will be unsubordinated obligations and will rank equally with all of our other senior unsecured and unsubordinated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indebtedness. Payments on the subordinated debt securities will be subordinated to the prior payment in full of all of our senior indebtedness, as described under &#147;Description of Debt
Securities&#151;Subordination&#148; and in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we may, but need not,
designate more than one trustee under an indenture. Any trustee under an indenture may resign or be removed and a successor trustee may be appointed to act with respect to the series of debt securities administered by the resigning or removed
trustee. If two or more persons are acting as trustee with respect to different series of debt securities, each trustee shall be a trustee of a trust under the applicable indenture separate and apart from the trust administered by any other trustee.
Except as otherwise indicated in this prospectus, any action described in this prospectus to be taken by each trustee may be taken by each trustee with respect to, and only with respect to, the one or more series of debt securities for which it is
trustee under the applicable indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement for each offering will provide the following terms, where applicable:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether they are senior or subordinated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities being offered, the aggregate principal amount of the debt
securities outstanding as of the most recent practicable date and any limit on their aggregate principal amount, including the aggregate principal amount of debt securities authorized; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the debt securities will be issued, expressed as a percentage of the principal and, if other
than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible into
common stock or other securities of ours or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if convertible, the terms on which such debt securities are convertible, including the initial conversion price
or rate and the conversion period and any applicable limitations on the ownership or transferability of common stock or other securities of ours received on conversion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities
will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or
rates is determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, from which interest will accrue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the record dates for interest payment dates, or the method by which such dates will be determined;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the persons to whom interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the basis upon which interest will be calculated if other than that of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any make-whole amount, which is the amount in addition to principal and interest that is required to be paid to
the holder of a debt security as a result of any optional redemption or accelerated payment of such debt security, or the method for determining the make-whole amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the principal of, and any premium or make-whole amount, and interest on, the debt
securities will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the debt securities may be surrendered for registration of transfer or conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be
served; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the times, prices and other terms and conditions upon which we may redeem the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or analogous
provision or at the option of holders of the debt securities, and the times and prices at which we must redeem, repay or purchase the debt securities as a result of such obligation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies in which the debt securities are denominated and payable if other than United States
dollars, which may be a foreign currency or units of two or more foreign currencies or a composite currency or currencies and the terms and conditions relating thereto, and the manner of determining the equivalent of such foreign currency in United
States dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the principal of, and any premium or make-whole amount, or interest on, the debt securities of the series
are to be payable, at our election or at the election of a holder, in a currency or currencies other than that in which the debt securities are denominated or stated to be payable, and other related terms and conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the amount of payments of principal of, and any premium or make-whole amount, or interest on, the debt
securities may be determined according to an index, formula or other method and how such amounts will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be in registered form, bearer form, or both, and (i)&nbsp;if in registered form,
the person to whom any interest shall be payable, if other than the person in whose name the security is registered at the close of business on the regular record date for such interest, or (ii)&nbsp;if in bearer form, the manner in which, or the
person to whom, any interest on the security shall be payable if otherwise than upon presentation and surrender upon maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions applicable to the offer, sale or delivery of securities in bearer form and the terms upon which
securities in bearer form of the series may be exchanged for securities in registered form of the series and vice versa, if permitted by applicable laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any debt securities of the series are to be issuable initially in temporary global form and whether any
debt securities of the series are to be issuable in permanent global form with or without coupons and, if so, whether beneficial owners of interests in any such permanent global security may, or shall be required to, exchange their interests for
other debt securities of the series, and the manner in which interest shall be paid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the depositary for securities in registered form, if such series are to be issuable as a global
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date as of which any debt securities in bearer form or in temporary global form shall be dated if other than
the original issuance date of the first security of the series to be issued; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability, if any, of the defeasance and covenant defeasance provisions described in this prospectus or
in the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances we will pay any additional amounts on the debt securities in respect of any
tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities in lieu of making such a payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances the debt securities being offered are convertible into common stock or other
securities of ours, as the case may be, including the conversion price or rate and the manner or calculation thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the circumstances, if any, specified in the applicable prospectus supplement, under which beneficial owners of
interests in the global security may obtain definitive debt securities and the manner in which payments on a permanent global debt security will be made if any debt securities are issuable in temporary or permanent global form;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions granting special rights to holders of securities upon the occurrence of such events as specified
in the applicable prospectus supplement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities of such series are to be issuable in definitive form only upon receipt of certain
certificates or other documents or satisfaction of other conditions, then the form and/or terms of such certificates, documents or conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the applicable trustee and the nature of any material relationship with us or any of our affiliates,
and the percentage of debt securities of the class necessary to require the trustee to take action; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any deletions from, modifications of or additions to our events of default or covenants with regard to such debt
securities and any change in the right of any trustee or any of the holders to declare the principal amount of any of such debt securities due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable CUSIP numbers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such debt securities not inconsistent with the provisions of the applicable indenture.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for less than the entire principal amount thereof to be payable upon
declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as &#147;original issue discount securities.&#148; The applicable prospectus supplement will describe the United
States federal income tax consequences and other relevant considerations applicable to original issue discount securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also may
issue indexed debt securities. Payments of principal of, and premium and interest on, indexed debt securities are determined with reference to the rate of exchange between the currency or currency unit in which the debt security is denominated and
any other currency or currency unit specified by us, to the relationship between two or more currencies or currency units or by other similar methods or formulas specified in the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described under &#147;Merger, Consolidation or Sale of Assets&#148; or as may be set forth in any prospectus supplement, the debt
securities will not contain any provisions that (i)&nbsp;would limit our ability to incur indebtedness or (ii)&nbsp;would afford holders of debt securities protection in the event of (a)&nbsp;a highly leveraged or similar transaction involving us,
or (b)&nbsp;a change of control or reorganization, restructuring, merger or similar transaction involving us that may adversely affect the holders of the debt securities. In the future, we may enter into transactions, such as the sale of all or
substantially all of our assets or a merger or consolidation, that may have an adverse effect on our ability to service our indebtedness, including the debt securities, by, among other things, substantially reducing or eliminating our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our governing instruments do not define the term &#147;substantially all&#148; as it relates to the sale of assets. Additionally, Delaware
cases interpreting the term &#147;substantially all&#148; rely upon the facts and circumstances of each particular case. Consequently, to determine whether a sale of &#147;substantially all&#148; of our assets has occurred, a holder of debt
securities must review the financial and other information that we have disclosed to the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide you with more
information in the applicable prospectus supplement regarding any deletions, modifications, or additions to the events of default or covenants that are described below, including any addition of a covenant or other provision providing event risk or
similar protection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we give you different information in the applicable prospectus supplement, the principal of, and any premium or make-whole amount, and
interest on, any series of the debt securities will be payable at the corporate trust office of the trustee. We will provide you with the address of the trustee in the applicable prospectus supplement. We may also pay interest by mailing a check to
the address of the person entitled to it as it appears in the applicable register for the debt securities or by wire transfer of funds to that person at an account maintained within the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All monies that we pay to a paying agent or a trustee for the payment of the principal of,
and any premium or make-whole amount, or interest on, any debt security will be repaid to us if unclaimed at the end of two years after the obligation underlying payment becomes due and payable. After funds have been returned to us, the holder of
the debt security may look only to us for payment, without payment of interest for the period which we hold the funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Denomination, Interest,
Registration and Transfer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, the debt securities of any series
will be issuable in denominations of $1,000 and integral multiples of $1,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations imposed upon debt securities
that are evidenced by a computerized entry in the records of a depository company rather than by physical delivery of a note, a holder of debt securities of any series may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange them for any authorized denomination of other debt securities of the same series and of a like aggregate
principal amount and kind upon surrender of such debt securities at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">surrender them for registration of transfer or exchange at the corporate trust office of the applicable trustee
or at the office of any transfer agent that we designate for such purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every debt security surrendered for
registration of transfer or exchange must be duly endorsed or accompanied by a written instrument of transfer satisfactory to the applicable trustee or transfer agent. Payment of a service charge will not be required for any registration of transfer
or exchange of any debt securities, but we or the trustee may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. If in addition to the applicable trustee, the applicable prospectus
supplement refers to any transfer agent initially designated by us for any series of debt securities, we may at any time rescind the designation of any such transfer agent or approve a change in the location through which any such transfer agent
acts, except that we will be required to maintain a transfer agent in each place of payment for such series. We may at any time designate additional transfer agents for any series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any trustee, will be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of or exchange debt securities of any series during a period beginning at the
opening of business 15 days before the day that the notice of redemption of any debt securities selected for redemption is mailed and ending at the close of business on the day of such mailing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt security, or portion thereof, so selected for redemption, in whole
or in part, except the unredeemed portion of any debt security being redeemed in part; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of or exchange any debt security that has been surrendered for repayment at the
option of the holder, except the portion, if any, of such debt security not to be so repaid. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger, Consolidation or Sale of
Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that we may, without the consent of the holders of any outstanding debt securities,
(i)&nbsp;consolidate with, (ii)&nbsp;sell, lease or convey all or substantially all of our assets to, or (iii)&nbsp;merge with or into, any other entity provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either we are the continuing entity, or the successor entity, if other than us, assumes the obligations
(a)&nbsp;to pay the principal of, and any premium or make-whole amount, and interest on, all of the debt securities and (b)&nbsp;to duly perform and observe all of the covenants and conditions contained in each indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the transaction, there is no event of default under the indentures and no event which,
after notice or the lapse of time, or both, would become such an event of default, occurs and continues; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an officers&#146; certificate and legal opinion covering such conditions are delivered to each applicable
trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Covenants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Existence</I>. Except as described under &#147;Merger, Consolidation or Sale of Assets,&#148; the indentures require us to do or cause to be
done all things necessary to preserve and keep in full force and effect our existence, rights and franchises. However, the indentures do not require us to preserve any right or franchise if we determine that any right or franchise is no longer
desirable in the conduct of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Payment of taxes and other claims</I>. The indentures require us to pay, discharge or cause
to be paid or discharged, before they become delinquent (i)&nbsp;all taxes, assessments and governmental charges levied or imposed on us, and (ii)&nbsp;all lawful claims for labor, materials and supplies which, if unpaid, might by law become a lien
upon our property. However, we will not be required to pay, discharge or cause to be paid or discharged any such tax, assessment, charge or claim whose amount, applicability or validity is being contested in good faith by appropriate proceedings.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Provision of financial information</I>. The indentures require us to (i)&nbsp;within 15 days of each of the respective dates by which
we are required to file our annual reports, quarterly reports and other documents with the SEC, file with the trustee copies of the annual report, quarterly report and other documents that we file with the SEC under Section&nbsp;13 or 15(d) of the
Exchange Act, (ii)&nbsp;file with the trustee and the SEC any additional information, documents and reports regarding compliance by us with the conditions and covenants of the indentures, as required, (iii)&nbsp;within 30 days after the filing with
the trustee, mail to all holders of debt securities, as their names and addresses appear in the applicable register for such debt securities, without cost to such holders, summaries of any documents and reports required to be filed by us pursuant to
(i)&nbsp;and (ii)&nbsp;above, and (iv)&nbsp;supply, promptly upon written request and payment of the reasonable cost of duplication and delivery, copies of such documents to any prospective holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Additional covenants</I>. The applicable prospectus supplement will set forth any of our additional covenants relating to any series of
debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Events of Default, Notice and Waiver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, when we refer to &#147;events of default&#148; as defined in the indentures with
respect to any series of debt securities, we mean: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any installment of interest on any debt security of such series continuing for 30 days;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of, or any premium or make-whole amount on, any debt security of such series
for five business days at its stated maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in making any sinking fund payment as required for any debt security of such series for five business
days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any covenant or warranty in the debt securities or in the indenture by us
continuing for 60 days after written notice as provided in the applicable indenture, but not of a covenant added to the indenture solely for the benefit of a series of debt securities issued thereunder other than such series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a default under any bond, debenture, note, mortgage, indenture or instrument: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">having an aggregate principal amount of at least $30,000,000; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under which there may be issued, secured or evidenced any existing or later created indebtedness for money
borrowed by us, if we are directly responsible or liable as obligor or guarantor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if the default results in the
indebtedness becoming or being declared due and payable prior to the date it otherwise would have, without such indebtedness having been discharged, or such acceleration having been rescinded or annulled, within 30 days after notice to the issuing
company specifying such default. Such notice shall be given to us by the trustee, or to us and the trustee by the holders of at least 10% in principal amount of the outstanding debt securities of that series. The written notice shall specify such
default and require us to cause such indebtedness to be discharged or cause such acceleration to be rescinded or annulled and shall state that such notice is a &#147;Notice of Default&#148; under such indenture; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy, insolvency or reorganization, or court appointment of a receiver, liquidator or trustee of us; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided with respect to a particular series of debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default occurs and is continuing with respect to debt securities of any series outstanding, then the
applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the principal amount of all the debt securities of that series to be due and payable. If the debt securities of
that series are original issue discount securities or indexed securities, then the applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the portion of the principal
amount as may be specified in the terms thereof to be due and payable. However, at any time after such a declaration of acceleration has been made, but before a judgment or decree for payment of the money due has been obtained by the applicable
trustee, the holders of at least a majority in principal amount of outstanding debt securities of such series or of all debt securities then outstanding under the applicable indenture may rescind and annul such declaration and its consequences if:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have deposited with the applicable trustee all required payments of the principal, any premium or make-whole
amount, interest and, to the extent permitted by law, interest on overdue installment of interest, plus applicable fees, expenses, disbursements and advances of the applicable trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all events of default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated
principal, or a specified portion thereof, and any premium or make-whole amount, have been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indentures also provide that the holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under the applicable indenture may, on behalf of all holders, waive any
past default with respect to such series and its consequences, except a default: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the payment of the principal, any premium or make-whole amount, or interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in respect of a covenant or provision contained in the applicable indenture that cannot be modified or amended
without the consent of the holders of the outstanding debt security that is affected by the default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in respect of a covenant or provision for the benefit or protection of the trustee, without its express written
consent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures require each trustee to give notice to the holders of debt securities within 90 days of a
default unless such default has been cured or waived. However, the trustee may withhold notice if specified persons of such trustee consider such withholding to be in the interest of the holders of debt securities. The trustee may not withhold
notice of a default in the payment of principal, any premium or interest on any debt security of such series or in the payment of any sinking fund installment in respect of any debt security of such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that holders of debt securities of any series may not institute any proceedings, judicial or otherwise, with respect to
such indenture or for any remedy under the indenture, unless the trustee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fails to act for a period of 60 days after the trustee has received a written request to institute proceedings in respect of an event of default from the holders of 25% or more in principal
amount of the outstanding debt securities of such series, as well as an offer of indemnity reasonably satisfactory to the trustee. However, this provision will not prevent any holder of debt securities from instituting suit for the enforcement of
payment of the principal of, and any premium or make-whole amount, and interest on, such debt securities at the respective due dates thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that, subject to provisions in each indenture relating to its duties in the case of a default, a trustee has no
obligation to exercise any of its rights or powers at the request or direction of any holders of any series of debt securities then outstanding under the indenture, unless the holders have offered to the trustee reasonable security or indemnity. The
holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under an indenture shall have the right to direct the time, method and place of conducting any proceeding
for any remedy available to the applicable trustee, or of exercising any trust or power conferred upon such trustee. However, a trustee may refuse to follow any direction which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is in conflict with any law or the applicable indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may involve the trustee in personal liability; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may be unduly prejudicial to the holders of debt securities of the series not joining the proceeding.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120 days after the close of each fiscal year, we will be required to deliver to each trustee a certificate,
signed by one of our several specified officers, stating whether or not that officer has knowledge of any default under the applicable indenture. If the officer has knowledge of any default, the notice must specify the nature and status of the
default. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification of the Indentures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that modifications and amendments may be made only with the consent of the affected holders of a majority in principal
amount of all outstanding debt securities issued under that indenture. However, no such modification or amendment may, without the consent of the holders of the debt securities affected by the modification or amendment: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the stated maturity of the principal of, or any premium or make-whole amount on, or any installment of
principal of or interest on, any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of, the rate or amount of interest on, or any premium or make-whole amount payable on
redemption of, any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of principal of an original issue discount security that would be due and payable upon
declaration of acceleration of the maturity thereof or would be provable in bankruptcy, or adversely affect any right of repayment of the holder of any such debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the place of payment or the coin or currency for payment of principal of, or any premium or make-whole
amount, or interest on, any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair the right to institute suit for the enforcement of any payment on or with respect to any such debt
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in principal amount of any outstanding debt securities necessary to modify or amend the
applicable indenture with respect to such debt securities, to waive compliance with particular provisions thereof or defaults and consequences thereunder or to reduce the quorum or voting requirements set forth in the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify any of the foregoing provisions or any of the provisions relating to the waiver of particular past
defaults or covenants, except to increase the required percentage to effect such action or to provide that some of the other provisions may not be modified or waived without the consent of the holder of such debt security. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in aggregate principal amount of the outstanding debt securities
of each series may, on behalf of all holders of debt securities of that series, waive, insofar as that series is concerned, our compliance with material restrictive covenants of the applicable indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our respective trustee may make modifications and amendments of an indenture without the consent of any holder of debt securities for
any of the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of another person to us as obligor under such indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants for the benefit of the holders of all or any series of debt securities or to surrender
any right or power conferred upon us in such indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add events of default for the benefit of the holders of all or any series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add or change any provisions of an indenture (i)&nbsp;to change or eliminate restrictions on the payment of
principal of, or premium or make-whole amount, or interest on, debt securities in bearer form, or (ii)&nbsp;to permit or facilitate the issuance of debt securities in uncertificated form, provided that such action shall not adversely affect the
interests of the holders of the debt securities of any series in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to change or eliminate any provisions of an indenture, provided that any such change or elimination shall become
effective only when there are no debt securities outstanding of any series created prior thereto which are entitled to the benefit of such provision; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to secure the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form or terms of debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the acceptance of appointment by a successor trustee or facilitate the administration of the
trusts under an indenture by more than one trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in an indenture, provided that such action shall not adversely
affect the interests of holders of debt securities of any series issued under such indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to supplement any of the provisions of an indenture to the extent necessary to permit or facilitate defeasance
and discharge of any series of such debt securities, provided that such action shall not adversely affect the interests of the holders of the outstanding debt securities of any series. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide
that in determining whether the holders of the requisite principal amount of outstanding debt securities of a series have given any request, demand, authorization, direction, notice, consent or waiver under the indentures or whether a quorum is
present at a meeting of holders of debt securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of an original issue discount security that shall be deemed to be outstanding shall be the
amount of the principal thereof that would be due and payable as of the date of such determination upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of any debt security denominated in a foreign currency that shall be deemed outstanding
shall be the United States dollar equivalent, determined on the issue date for such debt security, of the principal amount or, in the case of an original issue discount security, the United States dollar equivalent on the issue date of such debt
security of the amount determined as provided in the preceding bullet point; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of an indexed security that shall be deemed outstanding shall be the principal face amount
of such indexed security at original issuance, unless otherwise provided for such indexed security under such indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debt securities owned by us or any other obligor upon the debt securities or by any affiliate of ours or of such
other obligor shall be disregarded. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures contain provisions for convening meetings of the holders of debt securities
of a series. A meeting will be permitted to be called at any time by the applicable trustee, and also, upon request, by us or the holders of at least 25% in principal amount of the outstanding debt securities of such series, in any such case upon
notice given as provided in such indenture. Except for any consent that must be given by the holder of each debt security affected by the modifications and amendments of an indenture described above, any resolution presented at a meeting or
adjourned meeting duly reconvened at which a quorum is present may be adopted by the affirmative vote of the holders of a majority of the aggregate principal amount of the outstanding debt securities of that series represented at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the preceding paragraph, except as referred to above, any resolution relating to a request, demand, authorization, direction,
notice, consent, waiver or other action that may be made, given or taken by the holders of a specified percentage, which is less than a majority of the aggregate principal amount of the outstanding debt securities of a series, may be adopted at a
meeting or adjourned meeting duly reconvened at which a quorum is present by the affirmative vote of such specified percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
resolution passed or decision taken at any properly held meeting of holders of debt securities of any series will be binding on all holders of such series. The quorum at any meeting called to adopt a resolution, and at any reconvened meeting, will
be persons holding or representing a majority in principal amount of the outstanding debt securities of a series. However, if any action is to be taken relating to a consent or waiver which may be given by the holders of at least a specified
percentage in principal amount of the outstanding debt securities of a series, the persons holding such percentage will constitute a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions, the indentures provide that if any action is to be taken at a meeting with respect to any request,
demand, authorization, direction, notice, consent, waiver or other action that such indenture expressly provides may be made, given or taken by the holders of a specified percentage in principal amount of all outstanding debt securities affected by
such action, or of the holders of such series and one or more additional series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there shall be no minimum quorum requirement for such meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of the outstanding debt securities of such series that vote in favor of such request,
demand, authorization, direction, notice, consent, waiver or other action shall be taken account in determining whether such request, demand, authorization, direction, notice, consent, waiver or other action has been made, given or taken under such
indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subordination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, subordinated debt securities will be subject to the following subordination
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any distribution to our creditors in a liquidation, dissolution or reorganization, the payment of the principal of and
interest on any subordinated debt securities will be subordinated to the extent provided in the applicable indenture in right of payment to the prior payment in full of all senior debt. However, our obligation to make payments of the principal of
and interest on such subordinated debt securities otherwise will not be affected. No payment of principal or interest will be permitted to be made on subordinated debt securities at any time if a default on senior debt exists that permits the
holders of such senior debt to accelerate its maturity and the default is the subject of judicial proceedings or we receive notice of the default. After all senior debt is paid in full and until the subordinated debt securities are paid in full,
holders of subordinated debt securities will be subrogated to the rights of holders of senior debt to the extent that distributions otherwise payable to holders of subordinated debt securities have been applied to the payment of senior debt. The
subordinated indenture will not restrict the amount of senior debt or other indebtedness of ours. As a result of these subordination provisions, in the event of a distribution of assets upon insolvency, holders of subordinated debt securities may
recover less, ratably, than our general creditors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;senior debt&#148; will be defined in the applicable indenture as the
principal of and interest on, or substantially similar payments to be made by us in respect of, other outstanding indebtedness, whether outstanding at the date of execution of the applicable indenture or subsequently incurred, created or assumed.
The prospectus supplement may include a description of additional terms implementing the subordination feature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No restrictions will be
included in any indenture relating to subordinated debt securities upon the creation of additional senior debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this prospectus is
being delivered in connection with the offering of a series of subordinated debt securities, the accompanying prospectus supplement or the information incorporated in this prospectus by reference will set forth the approximate amount of senior debt
outstanding as of the end of our most recent fiscal quarter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Discharge, Defeasance and Covenant Defeasance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, the indentures allow us to discharge our obligations to holders of any
series of debt securities issued under any indenture when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either (i)&nbsp;all securities of such series have already been delivered to the applicable trustee for
cancellation; or (ii)&nbsp;all securities of such series have not already been delivered to the applicable trustee for cancellation but (a)&nbsp;have become due and payable, (b)&nbsp;will become due and payable within one year, or (c)&nbsp;if
redeemable at our option, are to be redeemed within one year, and we have irrevocably deposited with the applicable trustee, in trust, funds in such currency or currencies, currency unit or units or composite currency or currencies in which such
debt securities are payable, an amount sufficient to pay the entire indebtedness on such debt securities in respect of principal and any premium or make-whole amount, and interest to the date of such deposit if such debt securities have become due
and payable or, if they have not, to the stated maturity or redemption date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or caused to be paid all other sums payable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an officers&#146; certificate and an opinion of counsel stating the conditions to discharging the debt securities
have been satisfied has been delivered to the trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus
supplement, the indentures provide that, upon our irrevocable deposit with the applicable trustee, in trust, of an amount, in such currency or currencies, currency unit or units or composite currency or currencies in which such debt securities are
payable at stated maturity, or government obligations, or both, applicable to such debt securities, which through the scheduled payment of principal and interest in accordance with their terms will provide money in an amount sufficient to pay the
principal of, and any premium or make-whole amount, and interest on, such debt securities, and any mandatory sinking fund or analogous payments thereon, on the scheduled due dates therefor, the issuing company may elect either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to defease and be discharged from any and all obligations with respect to such debt securities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to be released from its obligations with respect to such debt securities under the applicable indenture or, if
provided in the applicable prospectus supplement, its obligations with respect to any other covenant, and any omission to comply with such obligations shall not constitute an event of default with respect to such debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, we may not elect to defease and be discharged from the obligation to pay any additional
amounts upon the occurrence of particular events of tax, assessment or governmental charge with respect to payments on such debt securities and the obligations to register the transfer or exchange of such debt securities, to replace temporary or
mutilated, destroyed, lost or stolen debt securities, to maintain an office or agency in respect of such debt securities, or to hold monies for payment in trust. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures only permit us to establish the trust described in the paragraph above if,
among other things, we have delivered to the applicable trustee an opinion of counsel to the effect that the holders of such debt securities will not recognize income, gain or loss for United States federal income tax purposes as a result of such
defeasance or covenant defeasance and will be subject to United States federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such defeasance or covenant defeasance had not occurred. Such
opinion of counsel, in the case of defeasance, will be required to refer to and be based upon a ruling received from or published by the Internal Revenue Service or a change in applicable United States federal income tax law occurring after the date
of the indenture. In the event of such defeasance, the holders of such debt securities would be able to look only to such trust fund for payment of principal, any premium or make-whole amount, and interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we use the term &#147;government obligations,&#148; we mean securities that are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct obligations of the United States or the government that issued the foreign currency in which the debt
securities of a particular series are payable, for the payment of which its full faith and credit is pledged; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obligations of a person controlled or supervised by and acting as an agency or instrumentality of the United
States or other government that issued the foreign currency in which the debt securities of such series are payable, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States or such other
government, which are not callable or redeemable at the option of the issuer thereof and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such government obligation or a specific payment of
interest on or principal of any such government obligation held by such custodian for the account of the holder of a depository receipt. However, except as required by law, such custodian is not authorized to make any deduction from the amount
payable to the holder of such depository receipt from any amount received by the custodian in respect of the government obligation or the specific payment of interest on or principal of the government obligation evidenced by such depository receipt.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, if after we have deposited funds and/or government
obligations to effect defeasance or covenant defeasance with respect to debt securities of any series, (i)&nbsp;the holder of a debt security of such series is entitled to, and does, elect under the terms of the applicable indenture or the terms of
such debt security to receive payment in a currency, currency unit or composite currency other than that in which such deposit has been made in respect of such debt security, or (ii)&nbsp;a conversion event occurs in respect of the currency,
currency unit or composite currency in which such deposit has been made, the indebtedness represented by such debt security will be deemed to have been, and will be, fully discharged and satisfied through the payment of the principal of, and premium
or make-whole amount, and interest on, such debt security as they become due out of the proceeds yielded by converting the amount so deposited in respect of such debt security into the currency, currency unit or composite currency in which such debt
security becomes payable as a result of such election or such cessation of usage based on the applicable market exchange rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we
use the term &#147;conversion event,&#148; we mean the cessation of use of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a currency, currency unit or composite currency both by the government of the country that issued such currency
and for the settlement of transactions by a central bank or other public institutions of or within the international banking community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the European Currency Unit both within the European Monetary System and for the settlement of transactions by
public institutions of or within the European Communities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any currency unit or composite currency other than the European Currency Unit for the purposes for which it was
established. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, all payments of principal
of, and any premium or make-whole amount, and interest on, any debt security that is payable in a foreign currency that ceases to be used by its government of issuance shall be made in United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that (i)&nbsp;we effect covenant defeasance with respect to any debt securities and (ii)&nbsp;those debt securities are declared
due and payable because of the occurrence of any event of default, the amount in the currency, currency unit or composite currency in which such debt securities are payable, and government obligations on deposit with the applicable trustee, will be
sufficient to pay amounts due on such debt securities at the time of their stated maturity but may not be sufficient to pay amounts due on such debt securities at the time of the acceleration resulting from such event of default. However, the
issuing company would remain liable to make payments of any amounts due at the time of acceleration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement
may further describe the provisions, if any, permitting such defeasance or covenant defeasance, including any modifications to the provisions described above, with respect to the debt securities of or within a particular series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and
conditions, if any, upon which the debt securities are convertible into common stock or other securities of ours will be set forth in the applicable prospectus supplement. The terms will include whether the debt securities are convertible into
shares of common stock or other securities of ours, the conversion price, or manner of calculation thereof, the conversion period, provisions as to whether conversion will be at the issuing company&#146;s option or the option of the holders, the
events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption of the debt securities and any restrictions on conversion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt
securities of a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf of, a depository identified in the applicable prospectus supplement relating to such series. Global
securities, if any, issued in the United States are expected to be deposited with The Depository Trust Company, or DTC, as depository. We may issue global securities in either registered or bearer form and in either temporary or permanent form. We
will describe the specific terms of the depository arrangement with respect to a series of debt securities in the applicable prospectus supplement relating to such series. We expect that unless the applicable prospectus supplement provides
otherwise, the following provisions will apply to depository arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a global security is issued, the depository for such
global security or its nominee will credit on its book-entry registration and transfer system the respective principal amounts of the individual debt securities represented by such global security to the accounts of participants that have accounts
with such depository. Such accounts shall be designated by the underwriters, dealers or agents with respect to such debt securities or by us if we offer such debt securities directly. Ownership of beneficial interests in such global security will be
limited to participants with the depository or persons that may hold interests through those participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that, under
procedures established by DTC, ownership of beneficial interests in any global security for which DTC is the depository will be shown on, and the transfer of that ownership will be effected only through, records maintained by DTC or its nominee,
with respect to beneficial interests of participants with the depository, and records of participants, with respect to beneficial interests of persons who hold through participants with the depository. Neither we nor the trustee will have any
responsibility or liability for any aspect of the records of DTC or for maintaining, supervising or reviewing any records of DTC or any of its participants relating to beneficial ownership interests in the debt securities. The laws of some states
require that certain purchasers of securities take physical delivery of such securities in definitive form. Such limits and laws may impair the ability to own, pledge or transfer beneficial interest in a global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depository for a global security or its nominee is the registered owner of
such global security, such depository or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the global security for all purposes under the applicable indenture. Except as described
below or in the applicable prospectus supplement, owners of beneficial interest in a global security will not be entitled to have any of the individual debt securities represented by such global security registered in their names, will not receive
or be entitled to receive physical delivery of any such debt securities in definitive form and will not be considered the owners or holders thereof under the applicable indenture. Beneficial owners of debt securities evidenced by a global security
will not be considered the owners or holders thereof under the applicable indenture for any purpose, including with respect to the giving of any direction, instructions or approvals to the trustee under the indenture. Accordingly, each person owning
a beneficial interest in a global security with respect to which DTC is the depository must rely on the procedures of DTC and, if such person is not a participant with the depository, on the procedures of the participant through which such person
owns its interests, to exercise any rights of a holder under the applicable indenture. We understand that, under existing industry practice, if DTC requests any action of holders or if an owner of a beneficial interest in a global security desires
to give or take any action which a holder is entitled to give or take under the applicable indenture, DTC would authorize the participants holding the relevant beneficial interest to give or take such action, and such participants would authorize
beneficial owners through such participants to give or take such actions or would otherwise act upon the instructions of beneficial owners holding through them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of principal of, and any premium or make-whole amount, and interest on, individual debt securities represented by a global security
registered in the name of a depository or its nominee will be made to or at the direction of the depository or its nominee, as the case may be, as the registered owner of the global security under the applicable indenture. Under the terms of the
applicable indenture, we and the trustee may treat the persons in whose name debt securities, including a global security, are registered as the owners thereof for the purpose of receiving such payments. Consequently, neither we nor the trustee have
or will have any responsibility or liability for the payment of such amounts to beneficial owners of debt securities including principal, any premium or make-whole amount, or interest. We believe, however, that it is currently the policy of DTC to
immediately credit the accounts of relevant participants with such payments, in amounts proportionate to their respective holdings of beneficial interests in the relevant global security as shown on the records of DTC or its nominee. We also expect
that payments by participants to owners of beneficial interests in such global security held through such participants will be governed by standing instructions and customary practices, as is the case with securities held for the account of
customers in bearer form or registered in street name, and will be the responsibility of such participants. Redemption notices with respect to any debt securities represented by a global security will be sent to the depository or its nominee. If
less than all of the debt securities of any series are to be redeemed, we expect the depository to determine the amount of the interest of each participant in such debt securities to be redeemed to be determined by lot. Neither we, the trustee, any
paying agent nor the security registrar for such debt securities will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in the global security for such debt
securities or for maintaining any records with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the trustee will be liable for any delay by the holders of
a global security or the depository in identifying the beneficial owners of debt securities, and we and the trustee may conclusively rely on, and will be protected in relying on, instructions from the holder of a global security or the depository
for all purposes. The rules applicable to DTC and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a depository for any debt securities is
at any time unwilling, unable or ineligible to continue as depository and we do not appoint a successor depository within 90 days, we will issue individual debt securities in exchange for the global security representing such debt securities. In
addition, we may at any time and at our sole discretion, subject to any limitations described in the applicable prospectus supplement relating to such debt securities, determine not to have any of such debt securities represented by one or more
global securities and in such event will issue individual debt securities in exchange for the global security or securities representing such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
debt securities. Individual debt securities so issued will be issued in denominations of $1,000 and integral multiples of $1,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of a series may also be issued in whole or in part in the form of one or more bearer global securities that will be
deposited with a depository, or with a nominee for such depository, identified in the applicable prospectus supplement. Any such bearer global securities may be issued in temporary or permanent form. The specific terms and procedures, including the
specific terms of the depositary arrangement, with respect to any portion of a series of debt securities to be represented by one or more bearer global securities will be described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Recourse </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no recourse
under any obligation, covenant or agreement in the applicable indenture or with respect to any security against any of our or our successor&#146;s past, present or future shareholders, employees, officers or directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_9"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the
material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will
describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms
described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the
purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from
these securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement.
We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the periods during which, and places at which, the warrants are exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner of exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreement and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal income tax consequences of holding or exercising the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may
issue units in such amounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us
and a bank or other financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series.
The specific terms of any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms
presented below. We urge you to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements
and unit certificates relating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the
holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time
or at any time before a specified date. The applicable prospectus supplement may describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable United States federal income tax considerations relating to the units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and of the securities comprising the units. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;Description of Capital Stock,&#148; &#147;Description of Debt
Securities&#148; and &#147;Description of Warrants&#148; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in
such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unit Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which
each series of units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provisions will generally apply to all unit agreements unless otherwise stated
in the applicable prospectus supplement: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification without Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, including modifying any provisions of the governing unit agreement that differ from those
described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to correct or supplement any defective or inconsistent provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of
the affected holders in any material respect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not need any approval to make changes that affect only units to be
issued after the changes take effect. We may also make changes that do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the
approval of the holder of the unaffected unit; we need only obtain any required approvals from the holders of the affected units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification with
Consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent
of the holder of that unit, if the amendment would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair any right of the holder to exercise or enforce any right under a security included in the unit if the
terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of outstanding units or any series or class the consent of whose holders is required to
amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any other change to a particular unit agreement and the units issued under that agreement would require the following approval: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects only the units of a particular series issued under that agreement, the change must be
approved by the holders of a majority of the outstanding units of that series; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects the units of more than one series issued under that agreement, it must be approved by the
holders of a majority of all outstanding units of all series affected by the change, with the units of all the affected series voting together as one class for this purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as the
governing document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each case, the required approval must be given by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unit Agreements Will Not Be Qualified under Trust Indenture Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act.
Therefore, holders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mergers and Similar Transactions Permitted; No Restrictive Covenants or Events of Default </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity or
to engage in any other transactions. If at any time we merge or consolidate with, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be
relieved of any further obligation under these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements will not include any restrictions on our ability to put
liens on our assets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements
and the units will be governed by Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form, Exchange and Transfer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the accompanying prospectus supplement states otherwise, we will issue each unit in global&#151;i.e., book-entry&#151;form only. Units
in book-entry form will be represented by a global security registered in the name of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests in a unit will do so through
participants in the depositary&#146;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the
issuance and registration of the units in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the accompanying prospectus supplement states
otherwise, each unit and all securities comprising the unit will be issued in the same form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue any units in registered, <FONT
STYLE="white-space:nowrap">non-global</FONT> form, the following will apply to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The units will be issued in the denominations stated
in the applicable prospectus supplement. Holders may exchange their units for units of smaller denominations or combined into fewer units of larger denominations, as long as the total amount is not changed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost,
stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions or perform them ourselves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders will not be required to pay a service charge to transfer or exchange their units, but they may be
required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder&#146;s proof of legal ownership.
The transfer agent may also require an indemnity before replacing any units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right
as to less than all those units or other securities, we may block the exchange or transfer of those units during the period beginning 15 days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the
list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being
partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments and Notices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_11"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also relates to the possible resale from time to time by the stockholders named herein, who we refer to in this prospectus as
the &#147;selling stockholders,&#148; of up to an aggregate maximum amount of 12,445,646 shares of our common stock in one or more offerings, subject to market conditions and prices, liquidity objectives and other investment considerations. Such
shares of common stock were issued and outstanding prior to the original filing date of the registration statement of which this prospectus forms a part. The selling stockholders originally acquired the shares of our common stock included in this
prospectus through (i)&nbsp;our initial public offering or otherwise on the open market, and (ii)&nbsp;several private placements of our common stock or convertible preferred stock prior to our initial public offering, with all such shares of
convertible preferred stock converted into shares of our common stock in connection with our initial public offering. Additional information about the selling stockholders, where applicable, will be set forth in an applicable prospectus supplement,
documents incorporated by reference in this prospectus or in a free writing prospectus we file with the SEC. We will not receive any proceeds from the resale of the common stock by the selling stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the information about the selling stockholders, including the number of shares of our common stock beneficially
owned by such selling stockholders immediately prior to the date of this prospectus, the number of shares offered hereby and registered by the registration statement of which this prospectus is a part, and the number of shares of our common stock to
be beneficially owned by such selling stockholders after this offering. The number of shares to be owned after this offering assumes that all shares covered by this prospectus will be sold by the selling stockholders and that no additional shares of
our common stock are subsequently bought or sold by the selling stockholders. Except as otherwise disclosed herein and in the footnotes below with respect to the&nbsp;selling stockholder, the&nbsp;selling stockholder&nbsp;does not and within the
past three years has not had, any position, office or other material relationship with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth below is based upon
information obtained from the&nbsp;selling stockholder. The percentages of shares owned after the offering are based on 28,055,344 shares of our common stock outstanding as of December&nbsp;31, 2018, including the shares of common stock covered
hereby. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;Prior&nbsp;to&nbsp;the&nbsp;Date<BR>of&nbsp;this&nbsp;Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Subject&nbsp;to<BR>Sale<BR>Pursuant&nbsp;to</B><br><B>this<BR>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;After&nbsp;Sale&nbsp;of&nbsp;All<BR>Shares&nbsp;Subject&nbsp;to&nbsp;Sale<BR>Pursuant&nbsp;to&nbsp;
this<BR>Prospectus(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,680,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,119,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,830,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,297,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quan Venture Fund I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">667,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts the&nbsp;selling stockholder&nbsp;may offer shares for sale.
The&nbsp;selling stockholder&nbsp;might not sell any or all of the shares offered by this prospectus. Because the&nbsp;selling stockholder&nbsp;may offer all or some of the shares pursuant to this offering, and because there are currently no
agreements, arrangements or understandings with respect to the resale of any of the shares, we cannot estimate the number of the shares that will be held by the&nbsp;selling stockholder&nbsp;after completion of the offering. However, for purposes of
this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the&nbsp;selling stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Voting and investment power over the shares held by PureTech Health LLC is exercised by its parent entity,
PureTech Health plc. The board of directors of PureTech Health plc consists of Mr.&nbsp;Joi Ito, Dr.&nbsp;Raju Kucherlapati, Dr.&nbsp;John LaMattina, Dr.&nbsp;Robert Langer, Dame Marjorie Scarino, Dr.&nbsp;Ben Shapiro, Mr.&nbsp;Christopher
Viehbacher, Ms.&nbsp;Daphne Zohar and Mr.&nbsp;Stephen Muniz. None of the members of the board of directors of PureTech Health plc or PureTech Health LLC has individual voting or investment power
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with respect to such shares. The address for PureTech Health LLC and the individuals listed above is c/o PureTech Health LLC, 501 Boylston St., Suite 6102, Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OrbiMed Capital GP VI LLC (&#147;GP VI&#148;) is the sole general partner of OrbiMed Private Investments VI,
L.P. (&#147;OPI VI&#148;). OrbiMed Advisors LLC (&#147;OrbiMed Advisors&#148;) is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares
held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. Jonathan Silverstein, a member of OrbiMed Advisors, is a member of the Company&#146;s board of directors. Advisors exercises investment and voting power
through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors, Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein disclaims beneficial ownership of the shares held by
OPI VI, except to the extent of its or his pecuniary interest therein if any. The address of these entities is 601 Lexington Avenue, 54th floor, New York, New York 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Quan Venture Fund I, L.P. is Ugland House, PO Box 309, Grand Cayman, Cayman Islands <FONT
STYLE="white-space:nowrap">KY1-1104.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PureTech Health LLC </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PureTech Health is a
greater than 5% stockholder and a founder of our company and in that capacity provided us with strategic medical, clinical and scientific advice pursuant to a business services, personnel and information management agreement until December 2017.
Daphne Zohar, PureTech Health LLC&#146;s founder and Chief Executive Officer, served on our board of directors until November 2018. David Steinberg is a member of our board of directors and previously served as
<FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Innovation Officer of PureTech Health, LLC until August 2018. PureTech Health LLC purchased shares of Series A preferred stock in our Series A financing in March 2017, August 2017 and
October 2017. We were a subsidiary of PureTech Health LLC until the closing of our Series B financing in November 2017. PureTech Health LLC&#146;s board designation rights terminated upon the consummation of our initial public offering. PureTech
Health LLC is entitled to the registration rights described in this prospectus under &#147;Description of Capital Stock.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>OrbiMed Private
Investments VI, LP </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPI VI is a greater than 5% stockholder that participated in our Series B financing in November 2017, in which it
obtained the right to appoint a representative to our board of directors. Although Jonathan Silverstein was OPI VI&#146;s representative prior to our initial public offering, OPI VI&#146;s board designation rights terminated upon the consummation of
our initial public offering. OPI VI is also entitled to the registration rights described in this prospectus under &#147;Description of Capital Stock.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and/or the selling stockholders, if applicable, may sell the securities offered through this prospectus and any accompanying prospectus
supplement, if required, in any of the following ways: (1)&nbsp;to or through underwriters or dealers, (2)&nbsp;directly to purchasers, including our affiliates, (3)&nbsp;through agents, or (4)&nbsp;through a combination of any these methods. The
securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. In the prospectus supplement
relating to such offering, we will name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay to any such agent. Any such agent will be acting on a best efforts basis for the period
of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any
applicable restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the
offering of the securities, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the agent or any underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering or purchase price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to the agent or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any exchanges on which the securities will be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A&nbsp;selling stockholder&nbsp;that is an entity may elect to make a pro
<FONT STYLE="white-space:nowrap">rata&nbsp;in-kind&nbsp;distribution</FONT> of shares of our common stock to its members, partners or stockholders pursuant to the registration statement of which this prospectus forms a part by delivering a
prospectus. To the extent that such members, partners or stockholders are not affiliates of such&nbsp;selling stockholder, such members, partners or stockholders would thereby receive freely tradeable shares of our common stock pursuant to the
distribution through a registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are used in the sale of the securities in respect of which
this prospectus is delivered, we or the selling stockholders, as applicable, will enter into an underwriting agreement, sales agreement or other agreement with them at the time of sale to them, and we or the selling stockholders, as applicable, will
set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with them. To our knowledge, there are currently no plans, arrangements or understandings between the
selling stockholders and any underwriter, dealer or agent regarding the sale of the shares covered by this prospectus by such selling stockholders. If any&nbsp;selling stockholder&nbsp;notifies us that a material arrangement has been entered into
with an underwriter, dealer or other agent for the sale of shares through a block trade, special offering or secondary distribution, we may be required to file a prospectus supplement pursuant to applicable SEC rules promulgated under the Securities
Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering of securities, we may grant to the underwriters an option to
purchase additional securities with an additional underwriting commission, as may be set forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set forth in the prospectus supplement for such
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we or the selling
stockholders will sell such securities to the dealer, as principal. The dealer, who may be deemed to be an &#147;underwriter&#148; as that term is defined in the Securities Act, may then resell such securities to the public at varying prices to be
determined by such dealer at the time of resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security
holders, we may enter into a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a
standby underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters,
dealers and other persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions
with or perform services for us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement, we will
authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus
supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom
the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our
approval. Delayed delivery contracts will not be subject to any conditions except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offered securities may also be offered and sold, if so indicated in the prospectus supplement, in connection with a
remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be
identified and the terms of its agreement, if any, with us and its compensation will be described in the applicable prospectus supplement. Remarketing firms may be deemed to be underwriters in connection with their remarketing of offered securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates, may be customers of, have borrowing relationships with,
engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in any offering of
the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed
securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any such underwriters
are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or the selling stockholders may engage
in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we or the selling stockholders may enter into derivative transactions with third parties, or sell securities not
covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the
applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use
securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the
applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an
applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle
in two business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date
for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities
initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a
national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will be described in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in
the ordinary course of business for which they receive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of offered securities will be set
forth in the applicable prospectus supplement relating to each offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Any
underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of resTORbio, Inc. and subsidiaries as of December&nbsp;31, 2017 and 2016 and for the year ended
December&nbsp;31, 2017 and the period July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public
accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_15">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the
SEC.&nbsp;Certain information in the registration statement has been omitted from this prospectus in accordance with the rules of the SEC.&nbsp;We are subject to the information requirements of the Exchange Act and, in accordance therewith, file
annual, quarterly and special reports, proxy statements and other information with the SEC. These documents may be accessed through the SEC&#146;s electronic data gathering, analysis and retrieval system, or EDGAR, via electronic means, including
the SEC&#146;s home page on the Internet (<I>www.sec.gov</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the authority to designate and issue more than one class or series
of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See &#147;Description of Capital Stock.&#148; We will furnish a full
statement of the relative rights and preferences of each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any shareholder upon request and without charge. Written requests
for such copies should be directed Investor Relations Department, resTORbio, Inc., 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116, and our website is located at<I> www.restorbio.com.</I>
Information contained on our website is not incorporated by reference into this prospectus and, therefore, is not part of this prospectus or any accompanying prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc723059_16"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important
information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information
already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or document that is not deemed filed under such
provisions, until we sell all of the securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017,
filed with the SEC on March&nbsp;29, 2018 and as amended on April&nbsp;27, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2018, June&nbsp;30, 2018, and September&nbsp;30, 2018, filed with the SEC on May&nbsp;10, 2018, August&nbsp;9, 2018 and November&nbsp;13, 2018, respectively; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;30,
2018, March&nbsp;19, 2018, March&nbsp;29, 2018, May&nbsp;9, 2018, May&nbsp;10, 2018, July&nbsp;25, 2018, July&nbsp;30, 2018, August&nbsp;9, 2018, August&nbsp;15, 2018, September&nbsp;18, 2018, October&nbsp;16, 2018, November&nbsp;6, 2018,
November&nbsp;13, 2018 and January&nbsp;7, 2019 (in each case, except for information contained therein which is furnished rather than filed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on Form <FONT
STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on January&nbsp;22, 2018, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered,
a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus,
at no cost by writing us at the following address: Investor Relations Department, resTORbio, Inc., 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116, telephone (857)
<FONT STYLE="white-space:nowrap">315-5521.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. We have
incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. Neither we nor
the selling stockholders have authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or
in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>7,200,000 Shares </B></P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g723059g92q50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>BofA Merrill Lynch </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SVB
Leerink </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Guggenheim Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Wedbush PacGrow </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March 19,
2019 </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g723059g23a75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g723059g23a75.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[15^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   *=V@ X0DE-!"4      ! G!5HE
M[<6#H;E>6VI=6T]S.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%_<L(         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/      0 ".$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              $T   $\
M          $                          0             !/    $T
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   $T
M    4F=H=&QO;F<   $\    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M&&M;]*RQQ=])%^J7_*C?^(?^6I#ZA4_H_6C92(%;Q?2.)8Z=]7_GVE6C7N$
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M6$DE/__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      $N34T *@    @ !P$2  ,    !
M  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (
M   >    <@$R  (    4    D(=I  0    !    I    -  $W)S   G$  3
M<G,  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP,SHQ
M." P.3HT,#HQ,@   Z !  ,    !__\  * "  0    !   !/* #  0    !
M    30         & 0,  P    $ !@   1H !0    $   $> 1L !0    $
M  $F 2@  P    $  @   @$ !     $   $N @( !     $
M $@    !    2     $X0DE- _T       @          /_A 3!-30 J
M"  ' 1(  P    $      1H !0    $   !B 1L !0    $   !J 2@  P
M  $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
MT    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C S.C$X(# Y.C0P.C$R   #H $  P    '__P  H ( !     $
M  $\H , !     $   !-          8! P #     0 &   !&@ %     0
M 1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
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M+D$I54K*@GP77<)@0.2I21Q)YQ6\\UEEV2U:,KE=3FCHW(ID;9 /L[MRIOQ
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MU'OO[) W]#V.P   XPE1'B W\A-MH -CQR;'B1)N9P1< >Q',WW=;S.WRO8
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M9_ K]U:OEW0N#"7/CK25'8+3)BLE)[[$>WJ-WII91J#)X'M5S39] X%()Y'
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M @IS9:29!F4-&PY N;$G\)(/KD%_W'=5D(44*5ISG"D*!V6%#&[)>Z=MB?F
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M3J]I:GVRIM##:'%N]80VA:EA!IE)3U555(^R!3;_ 'K>QU*2-D%)"BN!M2F
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M? U;2T]3$0.N**NEQ]QUP!?'/VH]2UVHJE*ZA:DT[:U*98!A*5$1O4 3N5M
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M.I&15CK<NKE9[/A642OFL*ZX\UF!%@0V79<900N,[,,D,K0E:$A24E)@_O\
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M0 #T 'X<98Q3R?K^I6*\&)/!]Q_#&%I*4E1"4@G;<@ $^OJ1Z_GP23R9QBD
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JQ/QM?%>#$X7!@PN#!A<&#"X,&%P8,+@P87!@PN#!A<&#"X,&%P8,?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g723059g38y52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g723059g38y52.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2/.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   IW: #A"24T$)0
M    $%$)'G\XEFEO J_Z"D H-CDX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8L)A
MP         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              &G   #PP         !
M                  $              \,   &G
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   &G     %)G:'1L;VYG   #
MPP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !IP    !29VAT;&]N9P   \,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     &9@
M   !    H    $8   '@  "#0   &7P &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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M\O)?-:22GZ6H'F/Q_N1QR/B/RKYB224__]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !
M+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M          #_X0$P34T *@    @ !P$2  ,    !      $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -    /      0   \     !061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP,SHQ." Q,CHP-#HR-@   Z !
M  ,    !__\  * "  0    !   #PZ #  0    !   !IP         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M4U5796:6L[2U1F1T=H8G8X23HJ.DI<+4UC<XA92V_\0 '0$! 0$  @,! 0
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M? 1VXAN(\Q^+@.F&/9BK33L%"#V5RS&KGQJYKDVW,U)?=E'W\_W/M8.D#G<
M:@&3I+>KYYTK;W;8_/\ Y=?WGR8HU;;_ .-58_7OW+I>U\J_]WL#[WFSJOQ6
MKD%S^L+'YRC]@PL(0L(0L(1^=K_=!P7R\Z./_OO6'UP3 -K:_5ZPQ]R\A7^>
M[\_]4)_^)1EMZH_,/W4E.2G)XZ_?U34?_1)G C\LYQX3'M8?SK6[M=>[G[-/
M5^GIM52GUDH8NS> V>N/Q#,&.3+6:D+4.L;&<,Q#94ZHU%.-[:#<0N/?<!T
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MODZY3W<J:FU7/.79C>4R[K+>%FG2%HM$Z7;%6"7+E2YDY!6;1:481T'2% G
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M8T6X=K%8)-T5TDV9N 'BRR2 ]37RIL]CO*_K'>DM-BD7++NN;SQ6I0M)MT_
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M&GC-O?2X#K?0+Z!X]PVUO;701&X=Y=MO&_ORB%(<4IVZFE<MF]MAS0B>]K
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MP/6XS%35HVE#B+:XE&P^C<=3"(!8-=@L-M0$=\27S*E*0)I,U!EO**2 RIB
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MC!IL$9 AM]P'AVM;L^W7<>=[C>^PX81_.;_D9ISZT^ZA&V'-_P"U[+-/(?\
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M006"9I&A$B=KGF@CU4K2+&]&C.J*R-KV?J>>I62K&#J;*^N\LI6&B9MO /\
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M7T!F/E_F91.8=>4+4<[EY55(.G-<4M3U7PLSEW3;ZGF<9,+4Y03*EWE*OR/
M.G&1T!'NH--+JHQ\8>K.EN5R,MEBM=W6R[;PL%DFV.7;9<U*K'>MIES#;+1+
MG!2$VJTSE)4D((.*8I*RK$I)+8<6ORCW1>UV6ZZK^L-]WE(,^[+5=DZ6N1=T
M_G;OL4^SJEWF+LL=CLDZSS9LU"TRI-F0$H!3L G(;I_,HH:5_P#DW>+!3<#T
M/H8W[86J1UQZ+L](3+MP"@10G*-6E>D;MP.)O-14KE PAQ&\4>3M9/.*OA/.
M*D7ZE83=ZQ+,Z^)T^:"!S19$H3@DT!)3T0DDJ/O97EJLDI,M/WBG!*57"I6%
M5H2E*;HLDB1-3*0/FIG3)1,I*E?)H("RIL(BZ8Z=Z%/1[UJ- /':[VKNEK4_
M6&GT#-TD^DS2A*<:L2(FCP$WS37XG[E94RGG4X%*4C4US!SVGR>RYMK$^5>J
MI4E:[@5.DBPJ!7]Z)G.3CB$IBJT%N;HG#7G#,!PCTTCRL(L]APHNVTS;>F5R
MP1(7/-IFV26>4EBE6:R**#\H18E(*YJ0H)6ADRL"B2F(?]+/**H\SJ'SCJC(
M=].5ZSIR(IFN0>U-#2E*N"05 .Z(C)VCZ3G:7DHIM+-70QM2-V=5%J*(;O(X
M6)6JJ+U1R3B'(>]C=IND7_9D65%H$R6N7=DY$\RC-G39LF=.EHES%I69B:),
MMP&HW2Y?A-Y/S+\3?\WD[;5VZ?=R;%;2HFU6=*T2D2TSK!8[9(M$BS3$+0F8
ME:D+4&P'H3%"'><G3;C,T*6S9IAMEY(PR&8N5&0>5[)RZFH$[J.2R3JZ6J,9
MEZE 4S3T496H&[Y%KY%#Q<0SCC$43:I)M2-TR>3<O(:;=ENNFUSKQD6I5VVN
M]+00FR6T<Z+Q3A3+3B)">;("\V,P!\72*N#E)Y3[%?E@O^[95W6Z3(O:[[@L
M5GFJD24VB5,N=),Z9/-GLTH+%IF!*4I2@!* IV<)'SQZL>_E;2Q;:[!KL.W?
M8?7CZ3A_VGZ&93_N^G7NCXSS8'UFT_@\\^.#/=K"ZL=+^%[#;6VH[]PZ@'=X
MCCC*B"1@FEOYF8W_ (?#5Z:1C"1]&<=AYB?D3_0.C>N/0%'4!&XWN(\7*]QO
M>UN[N[0CIC<M1*@<5IEH2^)*))=1TJJ4K*N6ZF4:2CI$E$P= I"_-Y_. DAB
MGHX14$%P?0UN*<Z768=!]'*)R&RZEZAH@Y*^K"JJEJ.!F4H\]10U5P<7"'I\
MYD&99%FFW-''<G7:OR'<^4*(',5,1QT[_(R[IO*6\+_O *M<NTHN\6>1.E6D
MF3,L:,)F3&PH7B4$*0C"0E2$J+&/H(\H-]V/D9=G):[;5:[+,LMHO*9;+:N2
MK\(LUNFI6FSH5+DHG2\(Q(6L34*4E:D528-4NF2T+#,8AW01Y!%ET,8CHGF2
M7G0*T>.(RK4JE5JU<J3,KA-H^33"/5BDUQ63364,D\ X 8?4)Y!2Q+<W@DVE
M=_WM>LVT>:VH3$V.WR)TJ19)*@*+DF8%*F%(3]%(8.>T2O*O9PCFK1=D^99T
M<G;JN:59T*M1E&U6"W2K5/MDT$AT3Y23+2@'&%E)*PD,GK=4?*!4A)%R^BJ.
MRXK'+&#H?,^5S(CU*!J#+ZG92!&9H-S2"M/4NTCLM6]/+Q;%RN#PQZRBJK?5
M Q5=QLT\,FH@=IZNS>3RV2E7B;1>5AM_G=FL=GEJM5FO<J'F]K5:)DV843T+
M*U)PHEA*Q+'2)0DX6]U;?+%=-H5=:++=5[7=9[LM%NM2#8D6*6H*M-E1(ERI
M-F%A-A,M*RM:U3Y$Z8M+.I2\1C?'_*(135&N8>%RLF,OH"6S:3SCI)UEC(Y=
MP]11U4GHR%I*8"5/467%1T\R+/J0;:><.J1@(%S%R+Q^E&"1LNH53,WR:6E7
MWOGHO*3:9\FQR[%;?/;-;9]E7+E*44>;(=,Q.!*S+'.KQ*2!B).:7Y:))E7G
M9%75>5DLEHO"T7A89UTRI-EMHFVA*!,-M6;(NSS#,6CG%"1)E)0MPA(2<(JO
MT8L\Z3R1S=5S<K"C:GKJ:8IU"K M8:J8ZGD4Y"K(V9A)]W,F>04L9_UL;-.#
M-2-#,03?)D=+ N BF7N/*/D_;[RNRRW5=EKE6>1+FR9TY=NLEHGSEKDK2L)E
MKE@8)6(?,+O1+AWCY[R*Y4W=R=O.\+VO6QWM>-JM"9TNSILA-GEHEVA$R5,,
MX+D*YR:9,Q0Q)2P))(+ BNU2K0CF?EW%,1DG#4\L_<JPD5,R:$Q)Q\:<WW*U
M>239E'-W;A(FAE4F#9,=BI$ ->R6:3/3*EIM:Q-G("<2Y-FG2D*5S80HA)"B
M 5!P"HD"A436.GWDNQ6FWVF?9+/:K-95*4FR2%R9BYDF3C,Q*)BTRTI6K&25
M%*0[TS$#_5GWX@^K3<!N'A^K?'EL,FF?H9K?^%H]=S6SG/T$\Z?T-&VBK5VY
MZLX#H8-A#3;7XOS$;#J-]>$J#L43BW\S,KG5L/J]49*2,DSCI^]YP!'6)>FC
M'WY(40OMRU^V]AW'3U\\0J^E@G L0#S4SQ&$[/9%"72I*A:@'!"429H06 %0
M4.3X-MBUF0'2FJ[H[T#G=3E"&DXFK<UV%!L8JLHJ1:M'5*%I&>=RS]5)%Q'O
M#.595FY!BF8JB1V@B99$Y3<1C]2OWDI9N4-\W);K8@JLMW&=YS9ER;0%6D+D
M39:4A<O"R,:QC!(QH!#B/H7)/EY;>2EPW[=5@E6B3;;T$CS2\$64+-C5*M$F
M;,F&7:),U,Q:D2E)E] X%J"ZGYO1LK>FQ(T.SR6^=%-2U;S65W2 J_/*<GW]
M2JFD:Q7JNEFM.J1SI5TW<+$>-U43N!?NW+TJJ(E1*BD013)Z^W\@T6M5^"3,
MEV:1>5CL=EL,I-EGK%W>:S)JU*EA2#1?..P)JI;Z1[^YO*G:;NE<G1;K-;;R
MM%TWI;[PO&>L3Y/WS3;)<B4F7,%GER4E2!+-5)PMA^D"8+TNG+1;#).:RMI_
M)UU2\E5%&4K3512U.3%+Q;=W/4S7S6LG5=$D4**"M%ZGJ4C?JGQ92J7L)".T
M&JL##-D^OZSU\OD);TWS+O&9>=E7)E6VV6E$M5GO-:L%HD<Q*E&SS"JPH$IU
M*Q2;/+F/0*8M'M)OE8NM/)17)^PW+;+!:)UELDJ=:K-)D2FM<BT"=-M*;1YH
MN\%XP,*46BU34@](RP0F#$/E%H5*H91PWRWGEF569:$H.NJ\?R&72^;E62+2
MID:GA:IEW@Y<&H&3D*?$B\"W"4HQVI*1B_ELDX-)E,LIZSX,[8J1(ES;SES3
M9YAF(E<Q>4RPH"D<VH2Y<V9SX!'34!,2A,TM+2F6D)'F'RRV,3[7AN:\%R+=
M=XLUIM\RQ7:J]I]I$^7/1-6I5W_>\IDX524'S0S%RDH,U2IKKBM-/=(BCENE
M"KG[FI04]G- HNBR36D:NJ*$1D7TG&1#2.IIY44A!4Q"P3YM"N&B3TL.SIQC
M%NA3;M'C9RS;BDMVFT<E+0;@EW18;RF71/#A=HE6:U)D%*E!4U,B4ZIB.<Z>
M,F82RLS'3KKY<78CEE;.4G*"Z+9?MDF)LR;'8;5(DH4GS:SB3+F6D6:RV>S+
MF(F)2MTR0ED@80#7F&?V9$#FUF5-YB0K&LF;RI_N^H0KJJH^K)9U/+BJDZ=H
MR$9#4\W08E8DCV4;&IL"(1K1J1FS*DQ*FV+V"XKL5=-V2;'/M"+1-LC2K,++
M9+3)LXL^:\4M>-2K0HE1YPJ9\PX!/5>5M[6*_+\M=[V&7>$OS\J5:I5YX[7.
M2LN$HLJI<F6F5*"2&1AIU1Q'@-O>V^P\Q&X7"]M]^_<-;8]QC_FYI_J9G;3#
MUCVQU?"1]"<-OR$Y]E.AZ<]CPNK-H&@6U\+^H-?&WOQR@. 6F!]#)FN/^[&^
M:!UF ,[&S3BQ[$;_ $]GL"B4  +>-K=WK'Z]1&^MA'&0H2I@F!$XD(4$_(S@
MQ(.;IWZ>P'<LJE+*FG*:7,P$6>;T9BT*0%?,-$N'=W'=%FNC_P!):J>CM2>=
ML30PR,75.;$#1\/%UA&/T63ZDE*:J09IPZ;D.V7\I,\:G49IBD=HHF8PF,H8
MNN.I7YR6LG*&]+FM=MEJF2+NEVQ%HLZY=K1YR+2A*4@3+.N4I(01B+J91 20
M028[MR1Y9VKDI<E_778//K-:K]5=Y7;[/9Y:UV7S*=.FKF2I=KLT^69ZTS>;
MEJPCFS\H#B37I>6G30F*09Y1'JR'G*WG\O>E#)])"HJ@D*D,J_K!W*4S$P*\
M0X=.45ETG0F8.%SOE#K%51?&1%),4P4/ZV^>0%CO2?>RI$S[WV6U73=EV7;)
ME61<PV$V&9-*YBS/EK*D+EK2E*9:DKZ-5C..S7+Y3YMT2>3\N=*O:\9EU\H+
MTON\K1/4N7-O8WG9D2ILJ:9$F6C%SR$3B5 IH4A-:ES7IMT6PR2J+*N)R=7I
M^1K"CC4O4DE 3%+1K%[(ES#8UO\ /$\BG17SX=U&_;MSQ:X/ZN7AXPS9DYB8
ME+@ZM+PSR)MZ[_1>T^]Y-LL\N9>,R79K9(O.=2UV>=(E2N9*_,Y:99F"8I4B
M3+5BHG(%/GS/*E=BN3QNBSW5;K#:U6:P25VFQR+-)29MEO6RV^;.,T63SR8J
M9*D+D($ZTSD$J25(PXH/%/E%(-.HWCMMEG-KMJFRKD\M*\KR3D<O'>;M4"O4
M;"I8";E)#^QO\R)Z0I5:+2B6[ZI:2E9&>CW;IQ-O5)!-)<? 5Y-;1-D(2;PD
MM+MAM$BQB1>4V[),LV9,A<J7+G35VIE*"IC&TB6A1 EH2CH'V(\L=B3;K3.1
M<]ME(METKL5HO*78KN-]6BTFVJM4FTSR;N^]<WFD8905-L$R>H J5,*PE<5/
MDL^(FIND2^SHK$,TI=@X4;),W,77L-3&9L4A'T['P$4_;U1!4DS@O+&2,<0@
MLRTVBT=1ZA(X5T2LTW"G<T\GYMDY-2;AL";&%"7+%K\ZL=NF6*>L6FTSYQ3*
M$TS4!8G@)(F@A6)1&0CHAY86>U\K[7RCO!-^\Q/EH1(78C+D7O(YB2F7*QV@
M61-EF(5AZ<I<E2$)0D2$HQ3"IETIL_D^D7F%$U>UI8:99T_0-)Y?ME9*42G:
MMJI&DV[A!.L*]J$D>Q+.5A*^5'&2>D9HE.5), 4$5#&)ODKR>F\G;L%@F6R=
M:$^<6BT\RB1-%DD3)YETLJ5H,Y"$I0S+FK!)*B,2B8\3EYRL3RSO07@FPF[Y
M<J5(DR4"QA=IGB2)H,^VVH2!,F6F8)G24A2$ =%BP*JU=6;M#S-SN'>([;VO
M;2][!SQV;#E292GXF;LH7P[.RK1T?FW^LW#S>>YT+NCV=L??S_<^X</2"SN
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MA_PK)_G</GZ]V'?_ -$_:/C[1P^&WDTWS+Q_1HW[N/0^+AR^_+ND[_/_ /\
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MUO3=\DGPZ/#Z1?BW<N&;]R=G^<--*<W3CL?I_(]]+M4;%5RE IKB!AKI[<
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M^&7T>\ !NMM(GQ:^6F8M-R@G46V:^RGX/72F[2%^Q#=,, _<*G0[KNY3>X@
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MH00H6$IM+:#W!SN'CO[.[NP 9]?=3B@WOG"/>-0A80A80A80@%S, 347+E*
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M[;=ON"WM\ P@/;X]WB(G&90$W#PD&P[V/<+<]#_'/D.(U#O.C>NG'9%@L9%
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MOYAY3_H+H.W/]U^ -\>@^4?RRN!BY?UX02B A?YOE UA"Y1,$T<P .XB4+@
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M\-OI0_67+-=1SEOE\Y6IP*.5<412BZM(@42A2JBL"P4/3@%, &*$&8PQ@%,
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M_F/UN7L_I]G?VJX]WV?ZV'.S/KIO]BR>GFMQX$3SA61$EO\ >Y7[<*X^_P
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MCJ^8?1$/W-E\@.+ZNP[A8YS^-K \8Y@ET/:T5,8/G52IC$.( 849<!L4; (
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MT+P&$AB_A7FO"-RB)=#!<!#B +@(:"A 8T6(/]M&Z@B8WTZ@#<QRG/805#A
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M(JR4$BNPG:MD8N1=-2% (EO%4G4%2.WZ;5-DX</0\BID6I6I!2.!G:BR9@4
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M?;5FS]OI,(D_,\1PE#S5'EMQ=DK5/@+Q#<W#<+]L>T:X;]]M3=7=LRA"\SQ
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M?D]_C5O;_=)O[''I9273XR"=1[]J@-:%5<L7C=,RM.%*0#JMU"!<2/U1UXK
M DL(CN VO1Y(.69(!L]@ V^>(+?]\1%>7OR?C*T6\G8;)-'I1%>V_2JRG3 H
M@I4(B( 8YAA3@-QL8W8\ITMW6"PZ8W\#W+ ?P=@/_,I?_P P^)WQQGR^<A*'
MG+<W^[S/[OC.)9+I<91$'56I!VL'F,X6'O 0<:[Z /KYX? ]RO;\58?UE'9_
M":]L/A\Y!U^5MWZM,\?DZ:;8E&_3#R>(83'/4NFXA!'':PA8/*==-.^_JU?
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M!Z<'=HW&L%$9TU%E5Z83G,NHJ);R6;DYE34TVTS#95%3%./8AU3;!)ZTD("
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M_+=3(_NHQR#73N&^UP]@^H.7CAB1]99_T@V?[3CPAS:R/X;N0#_Y?;PT9 0
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M3'.9DV,8QA&XF,84A$QA'41$1$1WPA#XI2D*4A"E*0I0*4I0 I2E*%BE*4+
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M2*/E_IC!\_<SOB^>43ZKDY^NVC_H1$BCT%,]UP*)$Z-*8]MZG&Q1Y /WL#0
M\0P^&3DII,O)Q_V*S]7\<VBOA1H#[GSRB:R^38W^>VC9_N!;N/KA\GT L_S!
M<0HH "W_ *3GU#U%C1^S8>8:B^&7DKESEX'_ )2333^-@[M<H?%\\HOU7)NF
M7X=:=[_Z!7-L_8/8_)_Y^?\ 4H;<OG0MM_HJVUM-/?A\,G)6OREX:T\SD_\
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M ,CG/9A$.G7ZC%A\(L+"$+"$+"$5.Z4WXA2/\><_GP6$(J 0+D(.PB4N@!W
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M@@]D+  7#RHP:^-BZW$-POWXGJV>'AV0@H9QX (?=L@-RG"_E)[W,6Q>6G:
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M7HQ4 WCG$G'RR+62C&II)O*#&-WS*/>JLQ3<.F**J@G51&8D$N=>-V79%/\
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M/A.03@4QE6J@D5!1X"9@$ERI&*N)E#N!78"0+NAD8[K!J%WQK0H2IH!DXUJ
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MRD28E.#A8AB "+5440$79E. ?-RQNIZI9R4&XQR9P36XK2"TF 9DXQCY-6)
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M$4!!/X;:E2EVF>J2 F4J:LRTC()*BP&X1^F+$B;+L=F1/.*<B1+3-('SI@0
MLMO+T[(=MK=G6][ (>_GST]O,==,<$>2,AQQZHFF'X0?;Z]AW_3A%@N:6T]W
M/?EJ.^]\<1=\WH2]-E<MN0A!HP'T0$>0 '=RUTUV[^X;AC>M *9TJ_:PWY[]
M809L?1V_._J^W33V\\74]0\7?T"$.\6$+"$+"$5RS8#]LA/Y)9_]Z\'P\/TW
MPA 2T +$]0::7M:_U^&MO;@8<>,$+3?W?;SPB'(MFT$S7TB]WAMX>'?C"OI5
M RU[]N= VK=]@T8[E]HC[P_2/CO[PR-=H%,J]1SI1NS.$&K'8/4 <][B'?\
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M@B158I 76(DF15P1(HE(1<Q2EZTH$,<A3'#K"E56 IB]>L*E&6;\<=L&$.;
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M1$3O2&X$#Q"B2AB]<8IOHA*N+<Y#).2RDLB[@Y:7C_$95'*58Y="*[68$XF
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M1APL1TS7HN !0A!;Y- !"SR,IU44@-)S@&$6H'(F1BAQ W29]<!#(1I52.%
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MK3L_:XZ% ?O9S'01&P %Q'0!Q81X^<T;U8J@C,<'7 W#C@)M(XK&$Y2AU:K
MAP3$Z:@"OP]44H 836.6[C+UY0AK,S[$(B4^AENW&OR!Q0DL 7.T6*%Q\C&P
M:ZB-M+ZX0BH+24;$$3'([N930"L'YO3 3EU\F =@U"W$ ]^&4(GFLTT$/P3^
MX?\ 1<F \_\ U/?4/KUQ..[KXU&V$3C><: )3]4_L90B86BY/?A VOW'X<KV
MOAF_NX[X>KWP;1\TTXA $),1*) ^CB)4X6MSLTTOL&FMA[L88AW8CL)?2CC;
MEG""YG/LR)F$6LQ8IN"P0DJ(Z% UP &E[:@'AOMC0?C=I1AWUS!&Q!4E.,TB
M\'D\NI81#C)"RG (@ :E-Y)VBZ^EL(@(!J XUQP[0C>$ZV'^XIJ_&)+!!RHB
M(APZ@ --0[5QML ".P80CV,TV RA?))@>K-PW+"R@E/VN'B(8&H@)1W >8;8
M0]&V/19]L@8%#LILUAT L'*"(V#B&YC-BD(4"@(B=0Q2W#AOQ& ,(AJ"-M/"
M*5(2";=9PB9L_.9-RZ(8R#0RZ0F!PL!N!5,QB*% ;@!RFL-KAJ.CCWP+:[Q$
MTWED"@ G:R9 ':\<X&XZ_O"F^NP#ROB/3N].QCZ.Z H&V00,YA&PB5I)B7Z,
M?Q!<-#Z!H;A'D(" @ CIAQUGC.GHBP71TLEN+23Y:>0+<_5IWW\=+[8R14-O
MUJXZ^K>/6@O8S[404 6DN44@)_P0^$#73$QN'A2$+$MPB.PCJ6Y<&J^=32F_
M7KV^G-!6RG&I" /DLN-[#^Y#X/S2CS2U]6-\<=\(D1FVH=;]R3/T1 /8(9^(
MJ73!3A1#JA%0Q;]68"WX5?HQ[6#Y;X1@)QJ/]RR^@ /[D/\ F #8?H=!#8;[
M" ARPA&1G&Y>MX64P<4DS*"!8AV!C@4@&X4P,0O$<W6!8A;B/".FF)2G?X'/
M9VPBJ=92B9ZRJ%0&DF *2"B@ +!8# "@%.!1#D8 -8?'#+M/J ]4(:(2J12\
M7D<H/"7B_$5=0#3PUU[^0^O%KQ]D(G6DFF4X&\DD['UT8*Z7"XAJ/</Q;#/@
MCCUP@N92B9@ ?))+U>;UO#NMS#<?;>^.,IR;JJ=WV9=C9P@OCIA,. 08RHW2
M X\,>L:QA.).$0#43!:_,+" :#<,:(J#OV5H#M/=WP@Q8S206+YOF+B-P^]B
MX6O\!X:>O%U[&)[J>)IG"'YI9,J@$\@EQNB17B!B6P">_P!'^,7XBV[7+4+8
ML(QYUT$P1DP)0 1XO(TPO;>P"XOIZN6$(]!*)CU5F$O]*D"OXB7L"*8J<!ON
MCTKAP7VXA#8,(17+-.2!:I4 \WRA!4B6HE [4H#]&JZN @"QA#?N&VN^(_'C
MQ[(FS9PT!C1^-K^0/^P(!^+[^\V^^GMV#0:TV@PX[8(6\AU8 (L9$;V&Q6]_
M&UA.'V_JQ>./3%,$K"1%0Y0*PD0[)AN9%(MP*%QT%>^MPMWCXAC"@[[3UN^F
M[0UIZ808L)03"%HV6'?0&J8B.H;AUX6Y_JVM0VVK=_#TJ==\(-F,F;L_>J8'
MLF$1!HF(%$NX?C%^U?LVTL&MN5%?;MU&SM#0B3"2$2D-YKF.WQ7#R-+L\)N'
M7[IL-]].0XL...-NR,><S:?>N8&XV_%$N?=]TW'OVVPA&/.A^J24\TS(=:!A
MX/(TN(G"82V-]TVN.X6OH.MAPA!)2CKRNHZ<-Y,[:\$N8.%XFFD<P^9)PHB0
MI%E;AK?M<(VOIA#9QH>-/5%<^GZQS"J^G(BBVV2C>J\MO.323F\T29P0F64I
M1)UX:IHR469OY5LJW@TSQ[H(E_+2Z,Q!OXV<>1#R%7\J(NW1N7F[LPI1W+C3
MW^#QU_H44@2D<GC)!2ZD$I+U YE5)IWFA#9P25;E&,BF+>IGU:03&-C7/"V9
M)0C)@T9MV[%A$-B(()$/P B*J2:=@9NR*C=+/-G+BF,U\X6V9]&Y8NLSJ0H&
MAI3HHIU5EC\\*AKBHWH2JCQO$RB;=P9VX"I>HA4(=?A2BE#(3*:9P%R55 "C
M];Z4IJWA6/K)"+OG4-$.I-J1E).8Q@O(,TKBFT?+-4E';5,1$1$B"YE$B7$1
MX2!<1'",Q6'I3@ L*1 >9YT.8;F@@';P$<(14),1 H#<US 4PW$UM>=MA[^7
MAMA$;LZO#/M#5SB53,/#OL.WJ^->_$(?C+C2D >,O#?$BW-<_:MP\(Z& +:V
M* " A;41L #S$.=L- ^S;NVO%B8;F#BN)Q#0!OU@@ @82@4=]>(1 H=]RE =
M0PTIU;=WAK""5H)C 4O$<0&P"7B,.XF +AM83$, :6XB" :AC%<0.^AW>NAX
M:$$S90]A$3& !*2YA$VRA3&3 1'40/PG,4!WX1,&PCC1W!VHQ RV^ANJNY!"
MV&P 6XAQ'!,2B.Z@<-DQ*.YKF+V1"^I1L CBC?H^G55Z\%M(01H<0%$;FT((
MEN.Q0#BWYEM<VNFYM]0!]>,]#40C> KFVXQ#A ^P^@;4#_Q1Y&V'OQ8/'CZ4
M $>)6VEQXU!"US% !'B$.&X'* ;:&  M?"'''A"%50;=L^@  =H= #0 #7D&
MGJPA&.(W$)N(W$(<(CQ&U#;AM?4MM.':URVL(AA" /,LQBT3,@!C 421P#VS
M6'BFH^X:\K:6 ;AZL-G'';"*8U76$=13.*D)5PW91K^<;PSQ^[7%!)@V=QTJ
MZ.Z*/4*\:Y5&"*:29CI@;K3^D-N%GOW,_5"(B*SKI%V@Z<D<K/D#STU'1*=/
M,7DT^D(^!9Q:TG+@U2:W;L&)Y A%0<*$XQ,4K1P_5,5#$.RG;[.MH01.<Y*%
MCD_*!?R+^-!K"N7LO#4Y,RL:S;5(D1:&([D6K11JS>222J*J*+@J(M4U$G$H
M6-;*HJN+X\9?;Z(0_89K1LM4]+0L%&33R.GY*LX56;7@Y5DQ:2-(\23I-!95
MHKQ-_."+EH9VH4R)Q0,"!CJ6(9#LXVZ^J)!OG!$-*PK.&G9*F(F,HU19JNDH
M[E7-5/D$H*%EC/TH=M"F9J-C.Y@C(B3=\=^X41(FV:J.#F2#+.*:[<J]]=7V
MEZPB<5SJA2*.FL85XWEH,PC,0M3P530K\Q7-(U;4L*W9$>Q;=N5:3"E570KK
M*$:)Q8KIG )<S=J(BOOV&K[:=>O:CI#;->D&-)A5\P\.A'M7SV+E'#=@\<$:
MR\-$/925:$34;I.3MT&L=(K%5Z@ICF12*!/PA!K#9QPW=U0B29YW9?$<L45W
M4NU!XC3[A9TZI2>1;02-5**MZ=4J)0[2T:>8,V^XVSOJ%T6SB/<OO)6[LJN
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M-JS^K!K0#^#]FR&*2:\\L;?E)=#LJFG:\%*(&,0@&)N!.  2*7LG%,$^$ *
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M #"_7IK[<6$8L'<'N#[+6Q&'KA'K81L4EQW[!.7LQ817'-G6ID#<1NQ%-.$
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M!,G]>9Q+*3SC,*IW:%>4U'5-5U,R=)Q%*KJ)0]/.J=%:%?J/4I )AI'MDI*
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M&*LMF44G!)8393I,L,,6+,E8I]',8BE2,!4DRK-@6BT)"PF=;!BES0"+0:@
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M",1 X+MX)1$*?$5#Q0PSHN67(FR6<8E&5)(4A&$E(+]":2*3U N4H(94P'G
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M8"F5(&I4Q!9HS GN.<DD#Y27\Y#_ "LEE/-#U&8Z:7)=R6) 5TO0#G 2\B<
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M?&,"IP.Z'KCF>B<Y5 6*<5' JKJ<<@HO4S) =IB*)2",2'2&FB@:@I0XJE(
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MD$#"H5)DJ501-QFZP';1B_ ][B]CF"X=MJ3'*BU6G"!+7:L!=A*6M*/Y5$J
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MP[4_R$C_ (4_DAJ?-&[?A%'R9(2<0%.7AT,"75$3X0"P)<";9F2R/ 7[B:F
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MR&OFEBHS'F9-&PLQPZ84L-R=@C:1A&)D B48Q0 !() 19MD^K.B+3J#D J
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M60*RITCI1F1J9VB9\5T<J:0$(DHN9EUAD2\).$@FX0X"6 H%"ST:1./LK3=
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M+H$4[#C #:A<)Q.UPO80*7?8-\03%NP4KM4JE-2YZMU,ZB##8.X03)%G>I(
MNHD3 8XC:*> '")KD)K/?F%$"W -;7YW'>-1^FK^T?;N@PV#N$; 0F=!%Y%#
MJ F#S6^N(7 3!?SYS"X;XF)?Y2G_ *1;N??[X,-@[HVIHRX$L9[$"?K0-Q&B
M'8W1 QS"B #*K"'&44R<7$%NJO;M"(L2_P I7><N_M\-\/=WY;N-,H83*4L,
M1*"+V*TCGPF!.*7*(E!JL)@N:0M82WOK?%Q*_*5WF##9QG%.VX2!U!!-5H0
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M4CXF,E'$U+2\*FFAYREI:$!J];)R0.8\Z3Z*3*@L\311E591*/C!<O6+M,*
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M=23<0YWT-;ZM.?+P[A <3FT$N><!-:++;P*9=W>\1I&DD5SHD^)#][[(SU)
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M.GX&E4ZHKIQ4453=,RQI:'AX?YMTU#-&Z2GFZ*1;.55XEXLY8,V"$<Q R*+
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M/47;#C=$X]?5XM$LF69X0^EB?'[G>:__ (P/CN#$]^G'9V18?$"9+J5:) W
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M>'M*2H&O:X6 +6]>F>CD6UV9Y&G8X=]-PA$ZV;39BDXIEL7LFO\ >,/2XAL
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M*5<,DEU$T7#M0"&$H@(H@]9X[_;$/TIOQ&D?\9.?SX+"+%0$]2%[N$E]]1L
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M&G4,/,U.O5E+TF:G&4LV*^;/JFJ*%IY4%;)*)'>1 S;63?QH+F?-&S94'39
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M]Q1]EN>P_'LN/'%/3 C#G36/AGTXW+A/I SI2+JI@$-#V*510  .!P-@X3
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M8?5A Q3[,2G*<EJZG',K 0<FZ!9%$'$A#QCY?JTVJ'"F"[MHLJ"93=8)2<?
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M[=1OUVYP@B0I*IDK6IR6*',/*J6-KWW&I &P_5R#%''&4(=?-:HK?D[,7_\
M::7MR_ZR^O\ HPA"^:U0_P![LQX?=-+_ /\ )/U]]N6'?X5U]W>=D2N[?7W>
MR%\UJB_O<F/'[II?ZOVR_;[QP[_#AO'MA7=W^Z.-5WE#F%4,VF^CZ:>"V!DF
MU."TG2R1P,DHX,4X%\_"-@*H6Y>/6X@(Z#B5^WMS;PBP-(Y&YF)A8U,N!MM]
M]:7VM;^^'U?&UA$LADUF.F);TP[MIQ6EJ6WW&WW\OORN/KM805XXX],Z^/'C
MPB>:Y3UX00%2FWA0#<OG.FC#>V]RSX!81Y6N&NHWQDI?CQW'MJP!BP1,\O*U
M1L*M-O[A?4C^F1W'N&H0#8+>WUX$=^=/4YIF3GO:K0@E:4?4Z7X6G98/ KFE
MQL >/SD#?VXK.SD]AU^W+9LTA#\:6J'^]R8__P!JE@^RI!T^+=].XGN'=K[8
M=?'@(7S6J&_Y.3%O%S2_Z*E_5^M$KN?K]WJA?-:HO[W)@0_]JI<-?^T@Z8@?
M?U%O5W1>OCP$2E/TO41*AB7;F*4CV$<X.\77?/(P53_>^08IMVS:,>RHJJF4
3=@LJHNLS222  3\H4,)4K"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g723059g92q50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g723059g92q50.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( $P!/ ,!$0 "$0$#$0'_Q  =   # 0$! 0$! 0          "0H(!P4&
M @,$_\0 21   00" 0," @0("@<) 0  ! $" P4&!P ($1()$Q0A%2(QMA89
M,C<X05=W%R,Y475VE9;6US5"6'&TM;<8)"4F,S125&%B_\0 '0$  00# 0$
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M[R1K6BU@CD:^1L<;C39#+(AJEFD/?*[9^UL?LW;]# XY1X=6,&Q8[0LEV[(
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M^ N>7]CA@O\ >#'_ %=3_7&O=^S)W/\ [I9/ZYR']W]'XWW9O^RD3_>[(/\
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M/6V53<UWQ9LKUBI9V5I);8*PVPL QQR/+U'P_P /S?3I2GCU]#\>/CJF"OL
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M\C=1%R6=R+1SY2\J'N6'Q(XXHJM-'^<E2K%%&6"23F>=1,=/\X33J:7QU>]
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#-?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
